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ABSTRACT
EVOLUTION OF PROSTATIC ACID PHOSPHATASE (ACPP) EXPRESSION IN
HOMINOIDS

By
Kathryn A. Hooper-Boyd
July 2008

Thesis supervised by Dr. Michael Jensen-Seaman
Hominoids vary in their mating behavior. Levels of sperm competition vary
accordingly. Species in which females mate with a large number of males are expected
to experience high levels of sperm competition, such as chimpanzee and bonobo, while
polygynous gorillas likely have little or no sperm competition. Coding regions of several
seminal proteins have been shown to be experiencing positive selection, but little is
known about the regulatory regions of these genes. The 1.7 kb upstream promoter region
of prostatic acid phosphatase (ACPP) of human, bonobo, gorilla, orangutan, gibbon, and
macaque was cloned into a luciferase reporter vector and transiently transected into a
human prostate cancer cell line (LNCaP). The in vitro expression levels were measured
and were found to vary. These results are discussed in terms of mating behavior, sperm
competition, and the influence of regulatory regions on phenotypic adaptations.
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Chapter 1
Introduction
1.1 Primate Mating Systems
Much variation exists in the social and mating behavior of the hominoid primates
(apes and humans) (Figure1). Adult gibbons (Hylobates) live as a monogamous, mated
pair with dependent offspring (Fleagle, 1999). They are the smallest hominoids and do
not exhibit sexual size dimorphism. Male investment in infant care is variable among
gibbon species, however males and females will jointly defend their home territory
(Fleagle, 1999). Orangutans (Pongo) are solitary animals and have traditionally been less
studied than other hominoid species. They exhibit a large degree of sexual size
dimorphism. They are considered to have a dispersed social system with males having
overlapping ranges that may allow females to mate with more than one male during a
reproductive cycle (van Schaik and van Hoof, 1996). Gorillas (Gorilla) live in groups
consisting of one dominant mature male (silverback) and several adult females with
dependent offspring (Watts, 1996). They are the largest of the hominoids and exhibit
extreme sexual size dimorphism (Fleagle, 1999). Males often display aggression towards
other males, especially unrelated males, and frequently engage in male-male conflict
(Watts, 1996). The strong degree of physical competition between males sustains a
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polygynous mating system, in which a dominant male has relatively complete
reproductive access to mature females in the group (Watts, 1996). Chimpanzees (Pan
troglodytes) and bonobos (P. paniscus) are the closest extant relatives of humans. There
is little sexual dimorphism in these species. They live in large social groups consisting of
a several adult males, several adult females, and dependent offspring (White, 1996).They
hunt and defend territory cooperatively, with little overt physical competition between
males (White, 1996). In the large multimale/multifemale groups, females are
promiscuous and may mate with many males in a single reproductive cycle (Goodall,
1986). Human (Homo sapiens) social and mating behavior is difficult to classify because
much variation exists within the species. In most human societies, males will mate with
one or more females, while females mate with only one male. They are generally
classified as having monogamous or polygynous mating systems (Fleagle, 1999).
Macaques are representatives of the Cercopithecoids, or Old World monkeys, and are
often used as an outgroup for phylogenetic analyses of the hominoids. Macaques are
similar to chimpanzee and bonobo in their mating systems and live in large
multimale/multifemale societies. Females will mate with multiple males in a reproductive
cycle, and levels of sperm competition are high (Fleagle, 1999). It is of note that the
mating behaviors described above represent generally accepted mating systems, and
some degree of intra-species variation is likely.
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Figure 1: Phylogenetic tree showing the relationship of primate species and their
mating systems. Adapted from Fleagle, 1999.
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1.2 Anatomical Features Correlated with Mating Behavior
Mating systems are often associated with specific anatomical traits. Body size
dimorphism between males and females is typically greatest in polygynous species, such
as gorilla (Fleagle, 1999). Also, certain features of the testes, sperm, and semen are
commonly associated with species experiencing a high degree of sperm competition, such
as in multimale/multifemale groups. For example, relative testes size is larger in
chimpanzees and bonobos, than in hominoids in which there is little sperm competition
(Harcourt et al., 1981). Also, the seminal vesicles are larger (Dixson, 1998a) and the
concentration of motile sperm is higher (Møller, 1988) in species in which the female is
mating with multiple males during a reproductive cycle. Species with high female
promiscuity also experience a higher degree of semen coagulation than species with
monogamous or polygynous mating system (Dixson and Anderson, 2002). Chimpanzees
and bonobos form a copulatory plug, a mass of coagulated semen that forms inside the
vagina of the female (Tinklepaugh, 1930). It is likely that this plug is functioning in
sperm competition to prevent sperm from subsequent males from fertilizing the female
(Dixson, 1998b), however this has never been demonstrated conclusively. The copulatory
plug is only found in species with a promiscuous female (Dixson and Anderson, 2002). In
species where sperm competition is likely not a factor, there is a smaller volume of liquid
semen, with little or no coagulation occurring in polygynous gorilla (Martin and Gould,
1977).

4

1.3 Semen Physiology
A number of proteins have been identified as components of the
coagulum/copulatory plug. The majority of the protein constituents of semen are
produced in the seminal vesicles and the prostate. Collectively, these proteins function to
cause the coagulation or dissolution of the plug. Semenogelins, SEMG1 and SEMG2, are
the main protein components of coagulated semen (Tauber et al., 1980) Human prostatespecific transglutaminase, encoded by TGM4, is responsible for cross-linking the
semenogelins, leading to semen coagulation (Porta et al., 1986). ACPP encodes another
protein of importance, prostatic-acid phosphatase. Aliases of this gene include ACP and
PAP .This protein functions as a proteolytic enzyme responsible, along with other
proteases, for the dissolution of the plug (Brillard-Bourdet et al., 2002)

1.4 Positive Selection on Seminal Proteins
Semen from different males overlap inside the female reproductive tract in
species where females mate with multiple males in a short period of time. In these
promiscuous species, the seminal fluid proteins are involved in interactions between
semen from different males. These reproductive proteins are candidates for positive
selection because of the strong adaptive pressures that are placed on them (Clark and
Swanson, 2005). A number of seminal protein genes are currently under positive
selection in chimpanzee (Clark and Swanson, 2005).These genes are involved in either
the coagulation (TGM4, SEMG1, SEMG2) or dissolution (ACPP, Kallikrein2 (KLK2),
prostate-specific antigen (PSA)) of semen and the copulatory plug. Other studies found a
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loss of function of seminal protein genes in species where there is little or no sperm
competition. Examples include the existence of SEMG1 and SEMG2 as pseudogenes in
gorilla (Jensen-Seaman and Li, 2003) Also, SEMG1 in certain gibbon species, and TGM4
in gorilla and some gibbon species (Clark and Swanson, 2005; Carnahan and JensenSeaman, 2008) are non-functional.

1.5 Regulatory Evolution
Expression of the genes coding for seminal proteins, as with any protein, is key to
the relationship between genotype and phenotype (Wray et al., 2003). According to King
and Wilson (1975), the large phenotypic differences seen between humans and
chimpanzees is not likely the result of changes in protein coding sequence alone, but it is
more realistically the result of changes in the expression of these proteins. An example of
changes in regulatory regions with significant phenotypic consequences is lactase
persistence in human populations. A single nucleotide polymorphism (SNP) in a cisregulatory element causing an increase in transcription of lactase is the genetic basis for
lactase persistence (Bersaglieri et al., 2004; Tishkoff et al., 2007). Another example is a
cis-regulatory SNP that prevents the binding of transcription factor GATA1, responsible
for expression of Duffy protein (DARC) in erythrocytes, but not other cell types. This
SNP provides malaria resistance for those individuals who have that genotype
(Tournamille, et al., 1995). Identification of gene regulatory elements may contribute to
the understanding of the mechanism by which variation in expression exists between
species of primates.
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1.6 Eukaryotic Transcriptional Regulation
Initiation of eukaryotic transcription of protein-coding genes is achieved by RNA
Polymerase II aided by a number of general transcription factors (Campbell, et al., 2003).
These general transcription factors function to correctly position RNA Polymerase II at
the promoter, separate the double-stranded DNA, and release RNA Polymerase II from
the promoter after initiation of transcription (Alberts et al., 2002). Certain DNA
sequences are common at the promoter of most protein-coding genes. These DNA
sequences are recognition sites for many of the general transcription factors and
complexes that form at the promoter. One important sequence is the TATA box that
binds a subunit for transcription factor TFIID. TFIID is an important landmark for the
assembly of the transcription initiation complex (Alberts et al., 2002). While general
transcription factors are important in initiating transcription in the proximal promoter,
many elements that also influence regulation of transcription can be found a great
distance away from the promoter. There are thousands of proteins in the human genome
that may function as transcriptional regulators. These regulatory elements may be found
upstream or downstream of transcription start, and can function as positive or negative
regulators of transcription (Alberts et al., 2002).

1.7 ACPP Regulation
Prostatic acid phosphatase (ACPP) is found in high concentrations in seminal
fluid. ACPP, among other proteolytic enzymes, is responsible for cleaving the main
protein constituents of semen, the semenogelins, resulting in a degradation of coagulum
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shortly after ejaculation (Brillard-Bourdet et al., 2002). The function of prostatic acid
phosphatase in degradation of semen and the copulatory plug makes it a likely candidate
for positive selection in species experiencing sperm competition. In fact, the coding
region of ACPP has been shown to be under positive selection (Clark and Swanson,
2005). Characterization of the promoter region of ACPP in human has also identified
elements that may have regulatory potential in this gene. Zelivianski et al. (2002)
determined that the sequence between -779 and +1 (where transcription start is +1) was
able to drive low levels of transcription in various cell types, however a dramatic increase
in prostate-specific expression is driven by the sequence located from -1258 to -779.
They also determined that the sequence of -1668 to -1356 had a negative effect on
transcription in a prostate cell line. Others determined that a downstream region from +50
to +467 may also be functioning in prostate-specific expression in mouse in vivo, but was
not demonstrated in transiently transfected prostate cancer cells (Shan et al., 2003). Shan
et al. (1997) identified a number of transcription factor binding sites in the -231 to +50
region, however none of these appear to be prostate specific. Potential androgen
response elements (AREs) have been identified in the upstream promoter region in
human ACPP (Virkkunen et al., 1994) and GAAATATGATA-like elements, which are
associated with AREs, have been found to influence transcription of ACPP in the
presence of androgen (Shan et al., 2003). However, it was also concluded that steroids,
including androgen, do not regulate expression of human ACPP in -231 to +50 reporter
constructs transiently transfected in an LNCaP prostate cell line (Shan et al., 1997).
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Chapter 2
Materials and Methods
2.1 Creating alignments and building trees
To obtain the nucleotide sequence of the 1.7 kb ACPP promoter region of each of
the hominoids, PCR and sequencing (see below) was performed on the following species:
chimpanzee (individual PR496, Pan troglodytes), bonobo (individual PR251, Pan
paniscus), gorilla (individual Josephine, Gorilla gorilla), orangutan (individual PR253,
Pongo pygmaeus), gibbon (individual PR598, Hylobates syndactyles), and macaque
(Macaca mulatta, individual NH3).The traces were analyzed and aligned in SeqMan
(DNAStar, Madison, WI) to create contigs and a consensus sequence of this region. The
human sequence was obtained from the UCSC genome browser (build hg18; NCBI build
36.1; Kent et al., 2002). Consensus sequences of the hominoids and human were aligned
in ClustalW2 (Larkin et al., 2007).

2.2 Characterization of the ACPP promoter
The human assembly from March 2006 was used in all analyses. The 2.2 kb
ACPP promoter was located in the UCSC genome browser (Kent et al., 2002) on
chromosome 3, position 133,517,148 to 133,519,347. Configuration of the genome
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browser plot was established by adding tracks containing various information. To
establish a general overview of the promoter of ACPP, the following tracks were used:
Base position, GC percent, RefSeq Genes, CpG Islands, SwitchGear TSS, and
RepeatMasker. In order to look at conservation of nucleotide sequence in the promoter
region, the following tracks were displayed: Base position, RefSeq Genes, 7X Reg
Potential (regulatory potential calculated from an alignment of human, chimp, macaque,
mouse, rat, dog, and cow), Conservation (conservation across 28 species of vertebrates),
Most Conserved (conserved elements predicted by phastCons based on a whole-genome
alignment of vertebrates and for the subset of placental mammals), 17-Way Conserved
(conservation in 17 vertebrate species), and 17-Way Most Conserved (conserved
elements in 17 vertebrate species based on phastCons predictions). Custom tracks were
added to the plot, including the area contained in the pGL4.10 [luc2] construct as well as
previously identified regulatory elements, by formatting the data to the GFF format.

2.3 Transcription factor binding site prediction tools
Transcription factor binding sites located in the ACPP promoter were predicted
using 3 software programs: TFSEARCH (Heinemeyer et al., 1998), MatInspector
(Genomatix Software GmbH), and Transcription Element Search System (TESS) (Schug
and Overton, 1998). For each of the programs, the default parameters were used in the
analysis. For determination of transcription factor binding sites predicted in conserved
regions of the human ACPP promoter, sequence entered into these programs was
obtained from the UCSC genome browser March 2006 assembly. Because prediction
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programs can generate a large number of false positives, the results were manually
compared to include only those transcription factor binding sites that were predicted by at
least 2 of the 3 programs for future consideration. For comparison of predicted
transcription factor binding sites at variable sites between species, sequence was obtained
by sequencing the DNA in the lab as explained below and was entered into the
TFSEARCH program with default parameters. The variable nucleotide plus 10 base pairs
before and after the nucleotide were put into the prediction program. Differences in
predicted sites between species were inferred through a manual analysis of the results.

2.4 Primer design
Primers were designed to cover the 3 Kilobase promoter region of ACPP and
ordered from Integrated DNA Technologies (Coralville, IA). This region consists of 2 kb
of upstream sequence and 1 kb of sequence downstream of the transcription start. To
design primers for use across hominoid species, the genomic sequence of human and
macaque were obtained from the UCSC genome browser and aligned using ClustalW2.
Primers were manually chosen in regions that are conserved between human and
macaque. The Sequence Manipulation Suite (Stothard, 2000) was used to rule out
hairpins after the manual choice of primer sequence. Primers were chosen with an ideal
length of 18-23 nucleotides and an annealing temperature between 55 and 60° C. Forward
and reverse primers were designed approximately 250 bases apart along the length of the
sequence in order to cover the 3 kb region in both directions. To design primers for use in
creating constructs containing 1.7 kb of ACPP upstream promoter (-1593 to +117, where
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transcription start site is +1), primers were given a 5` tail of approximately 10-15
nucleotides containing a restriction enzyme site. The forward primer contained a Kpn I
site while the reverse primer contained a Sac I site. Using separate sites for forward and
reverse primers ensures that the resulting insert will be ligated in the correct orientation.
All primers in this study are shown in Table 1.
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Forward Primers
Sequence
TGCAAGTTCCCTTGAATGGT
GAGAATGTGATGGCAAAGAG
CTCAGCTCAAAATTTACATGACA
GAACTGACAGGTTGGGGAAA
GAATCACTGGTCTAAGGTTTC
CAGCCACACCAGTCCAGAA
CCTTGAATGGTTAATCCTAATC
CAGTTCTCCCATATACCACAT
GTCCAATTGTCTTAAGGTGTG
CAACCTCCACCTCCTGGGTT
GCATGGAAATAGGCCCCAAAT
TATGTCAACACCTGTATTTCC
GATTGTGCCACTGTGCTCCA
ACGTGCTACAGGTACCACATTCCAGGGCATCCTATGATC
CTCCTCAACATGAGAGCTCCACC
AGGTGCCAGAACATTTCTCT
CGCCAGGGTTTTCCCAGTCACGAC
Reverse Primers

Name
ACPP_F1
ACPP_F1B
ACPP_F2
ACPP_F3
ACPP_F4
ACPP_F5
ACPP_F6
ACPP_F7
ACPP_F8
ACPP_F9
ACPP_F10
ACPP_F11
ACPP_F12
ACPP_pro1710KpnF1
ACPP_SacF1
pGL_4223_F1
M13 F

Sequence
CGAGAGAGGAAAGGCAAGAA
TTTCAAAAACTCTCATGTAGCCTAT
GGTCTCTGGGAAACAATCCA
AGGATGCCCTGGAATGTGG
TTAGTCACACCTTAAGACAA
TAGATAGGGTATGATACAGCGT
CTCTGTCAGGTTTGGAAAGG
GGAGCCACACTCATAAGTAGT
TCCATTTTCCCCAACCTGTC
TCTCATGTAGCCTATAGAGGTAT
TCTGTAATCCCAGCACTTTGG
CTGAGTAGCTGGGATTACAG
TGTTGGTTAGGCTGGTCTCCA
CACTATGCCTAAGCTTGGTGCAGCTCTGTTGAGGAGAGCTG
CTGTTTCCTGGAGCTCTGTTGAGGAGAGCTGTTTCTG
TTACCAACAGTACCGGATTG
GAGCGGATAACAATTTCACACAGG

Name
ACPP_R1
ACPP_R2
ACPP_R3
ACPP_R4
ACPP_R5
ACPP_R6
ACPP_R7
ACPP_R8
ACPP_R9
ACPP_R10
ACPP_R11
ACPP_R12
ACPP_R13
ACPP_pro338HindR1
ACPP_SacR1
pGL_92_R1
M13 R

Table 1: Primers Sequences for ACPP and pGL4.10 [luc2]
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2.5 Polymerase chain reaction (PCR)
Polymerase Chain Reaction was performed on genomic DNA using the Applied
Biosystems GeneAmp PCR System 9700 thermocycler. PCR conditions were optimized
for each primer and species. For PCR on genomic DNA amplified with the purpose of
sequencing the 3 kb promoter, a standard reaction was used. In a 20µl reaction: 1X
Eppendorf Taq DNA Polymerase Buffer (1.5mM Mg2+), 250μM dNTPs, 20.0µM forward
and reverse primers, ~20ng template, 0.5 U Eppendorf Taq, up to 20.0 µl sterile
molecular biology grade water . For PCR performed on template destined for constructs,
a proof-reading Taq was used. In a 50µl reaction: 1X Takara Taq DNA Polymerase
Buffer, 400μM dNTPs, 20.0µM forward and reverse primers, ~50ng template, 2.5 units
Takara LA Taq DNA Polymerase, up to 50µL sterile molecular biology grade water.
PCR products were column purified using Promega Wizard® SV Gel and PCR Clean-Up
System to obtain up to 40μg of DNA. PCR products were gel electrophoresed with a 1%
agarose gel made with 1X SB and visualized under UV light after ethidium bromide
staining. 4.0µl of PCR product was loaded into a well with 3.0µl of loading buffer. 1.5µl
of DNA ladder (Fisher exACT Gene Low Range DNA Ladder Plus) was also run along
with the PCR products to determine product size.

2.6 TOPO TA Cloning
Amplified PCR products of the ACPP promoter of each hominoid species and
macaque were cloned into a TOPO TA vector (Invitrogen). To ensure that the product is
correctly ligated into the vector, 3` Adenine-overhangs were added. In a 20µl reaction:
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10.0µl Taq amplified PCR product, 1X Taq DNA Polymerase Buffer (1.5mM Mg),
250μM dNTPs, 0.5 units Taq DNA Polymerase, and up to 20.0µl of sterile molecular
biology grade water. This reaction was incubated for 15 minutes at 72° C. The resulting
product was added to the TOPO cloning reaction. In a 6µl reaction: 0.5-4.0µl PCR
product, 1.0µl salt solution (1.2M NaCl; 0.06M MgCl2), sterile molecular biology grade
water up to 5.0µl, and 1.0µl Topo vector. This reaction was mixed and incubated at room
temperature for 15 minutes (longer time for larger products). The resulting TOPO
construct was transformed into One Shot® Top 10 chemically competent E.coli by
adding 2µl of the TOPO cloning reaction into a vial of cells. This was incubated on ice
for 15 minutes. The cells were then heat -shocked by placing them into a 42° C water
bath for 30 seconds. They were immediately transferred to ice and 250µl of room
temperature S.O.C. added. The cells were incubated at 37° C and shaken at 200 rpm for 1
hour. Last, 20µl, 50µl, 100µl, and 200µl were plated on pre-warmed Luria-Bertani (LB)
plates with the selective antibiotic ampicillin and incubated overnight at 37° C. The
TOPO vector contains an ampicillin resistance gene allowing only those colonies
containing the gene to grow on the selective plates.

2.7 Screening colonies for the presence of the ACPP insert
1 ml of LB medium with ampicillin was placed into a well of a 96 well culture
plate. Colonies were picked with a sterile toothpick into the 1ml of medium by touching
the colony, swirling the tip in the 1 ml of medium, and removing the toothpick.
Typically, 8-16 colonies were picked for each TOPO construct. These 1 ml cultures were
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placed in the shaking incubator at 37° C and 200 rpm for 6-8 hours. After the incubation
time, PCR was performed on each 1 ml culture in order to screen for the presence of the
insert. Primers used for the PCR include M13 forward and reverse primers (Table 1) as
well as ACPP specific primers designed to work across hominoid species by placing
them in a region that is conserved between human and macaque. To prepare the 1ml
culture to use as template, 5.0µl of the culture was added to 50 ml of sterile Molecular
Biology grade water and heated to 99° C for 15 minutes. In a 20.0µl reaction: 1.0µl
template (prepared as above), 1X Eppendorf Taq DNA Polymerase Buffer (1.5mM Mg),
250μM dNTPs, 20.0 mM forward and reverse primers, and 0.5 units Eppendorf Taq
DNA Polymerase. The resulting PCR products were gel electrophoresed in a 1% Agarose
gel made with 1X SB and stained with ethidium bromide and visualized under UV light.
An aliquot of 4.0µl of each product was loaded into a well with 3.0µl of loading buffer
along with DNA ladder (Fisher exACT Gene Low Range DNA Ladder Plus) to
determine product size. The presence of a band of the correct size on the gel indicated
that the colony contained the desired insert. A 50.0µl quantity of the corresponding
culture was placed in 50 ml of LB broth with ampicillin and placed in the shaking
incubator at 37°C and 200 rpm for 16-18 hours.

2.8 Midi-Prep plasmid purification
Purification of the TOPO plasmid was performed using a QIAGEN HiSpeed®
Plasmid Midi Kit or a QIAprep Miniprep. For the Midi-prep, the 1 ml starter culture was
diluted 1/1000 by inoculating 50 ml of LB containing ampicillin with 50μl of the culture.
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This culture was placed in the shaking incubator at 37º C and 200 rpm for 16-18 hours.
After the incubation time, the cells were harvested by centrifuging the culture in 50 ml
centrifuge tubes at 6000 x g for 15 minutes at 4ºC. The QIAGEN protocol for high-copy
plasmids in a 50 ml culture was followed to purify up to 200μg of high-copy plasmid.

2.9 Mini-Prep plasmid purification
To purify the TOPO plasmid using a QIAGEN QIAprep® Miniprep, the 1 ml
starter culture was diluted 1/100 by inoculating 5 ml of LB containing ampicillin with
50μl of the culture. This culture was placed in the shaking incubator at 37º C and 200
rpm for 12-16 hours. After the incubation time, the cells were harvested by centrifuging
the culture at room temperature in 15 ml conical tubes at 6000 x g for 3 minutes. The
QIAGEN protocol for QIAprep Spin was followed to purify up to 20 μg of high-copy
plasmid.

2.10 Sequencing
Sequencing was performed on an ABI 3100 Avant Automated DNA Sequencer
(Applied Biosystems). Both genomic DNA amplified by PCR and plasmid DNA cloned
in E.coli were sequenced using similar methods. ACPP primers were used for both
genomic and plasmid DNA, while vector specific primers were also used to sequence
constructs. These primers include M13 forward and reverse primers for the TOPO
vectors and pGL4.10 [luc2] primers manually designed to flank the restriction site
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containing the ACPP insert. Sequencing of the TOPO and pGL4.10 [luc2] vectors was
necessary to determine if the insert was correctly ligated into each. In a 20µl reaction:
2.0 µl BigDye v3.1, 1X BigDye v3.1 Buffer, 1-50 ng purified plasmid, 3.2 pmol primer,
and up to 20 µl of Molecular Biology grade water. The sequencing products were
purified using Sephadex G-50 as follows: 600.0μl of Sephadex G-50 slurry was added to
each well in a 96 well filter plate. The plate was centrifuged at 850 x g for 3 minutes and
the flow through was collected and discarded. The entire sequencing reaction (20.0μl)
was added to the top of the columns and was centrifuged at 850 x g for 4 minutes, with
flow through from each well collected in a 96 well plate. After Sephadex purification, the
samples were dried by placing them in the thermocycler at 90°C for 15 minutes. They
were resuspended with 10.0µl of Hi-Di Formamide (Applied Biosystems), vortexed,
denatured at 95°C for 2 minutes, and snap-cooled on ice. SeqMan was used to analyze
sequence traces and create alignments.

2.11 Making chemically competent E.coli
E. coli strain TG1 (a generous gift from Dr. J. McCormick, Duquesne University)
was streaked from a freezer culture onto an LB plate and incubated 16-18 hours at 37°. A
colony from this plate was picked with a sterile toothpick by touching the tip of the
toothpick to the colony and placing it into 3.5 ml of LB. This culture was placed in the
shaking incubator at 37°C and 200 rpm for 16-18 hours. 300 µl of the 3.5 ml E. coli
culture was placed in 30 ml of LB broth with no antibiotic (1 in 100 dilution) and placed
in the shaking incubator at 37°C and 200rpm for 4 hours. 20 ml of the E. coli culture was
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transferred into a sterile 50 ml centrifuge tube. This was centrifuged at 5000 rpm at 4°C
for 4 minutes. The supernatant was decanted and the pellet resuspended in 10 ml (1/2 of
original volume) of 50 mM CaCl2 and placed on ice for 20 minutes. Once again, it was
centrifuged at 5000 rpm at 4°C for 4 minutes and the supernatant decanted. The pellet
was resuspended in 2 ml (1/10 of original volume) of 50mM CaCl2. Freezer stocks were
made of the chemically competent E. coli by adding 1400.0 µl 50%gylcerol/50mM
CaCL2 solution to 2 ml of the cells and aliquoting 200.0 µl into 1.5 ml screw cap tubes
for storage at -80ºC.

2.12 Luciferase reporter vectors (pGL4.10 [luc2] and pGL4.70 [hRluc])
The firefly luciferase reporter vector, pGL4.10 [luc2] (Promega), and Renilla
luciferase vector, pGL4.70 [hRluc] (Promega), were cloned by transforming them into
chemically competent E.coli. A 200.0 µl freezer stock of E.coli was thawed on ice for 2030 minutes. 2.0 µl of the pGL4.10 or pGL4.70 plasmid was added to 200.0 µl of the
chemically competent E.coli in a 1.5 ml tube. After incubating for 20-30 minutes, this
was heat shocked by placing in a 42°C water bath for 2 minutes. 1.0 ml of LB broth with
ampicillin was added to the tube and mixed by inverting 3 times. This was placed
horizontally in the shaking incubator at 37°C and 200 rpm for 1 hour. 20.0µl, 50.0µl,
100.0µl, and 200.0 µl were plated on LB plates containing ampicillin along with a 0µl
control plate and incubated at 37°C for 16-18 hours. The pGL4.10 [luc2] plasmids
contain an ampicillin resistance gene, enabling only those colonies containing that gene
to grow on the selective plates. The following day, 2 colonies were separately picked
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with sterile toothpicks by touching the end of a toothpick to the colony and swirling it in
3 ml of LB broth with ampicillin. This was placed in the shaking incubator at 37°C at 200
rpm for 16-18 hours. An aliquot of 50.0 µl of the 3 ml culture was added to 50 ml of LB
broth containing ampicillin and placed in the shaking incubator at 37°C and 200 rpm for
16-18 hours. The plasmids were purified using the QIAGEN HiSpeed® Plasmid Midi Kit
protocol for high-copy plasmids in 50 ml culture as described above.

2.13 Cloning human androgen receptor (hAR)
Human androgen receptor (hAR) (cDNA clone; GenBank M34233; ATCC) was
cloned in E.coli by transforming it in chemically competent cells. To the freeze-dried
culture, 0.5ml of LB containing ampicillin was added. This was mixed and the entire
volume added to a 15 ml tube containing 6ml of LB with ampicillin. The tube was placed
in the shaking incubator at 37ºC and 200 rpm for 20-24 hours. It was then plated at a
volume of 100.0μl on an LB plate with ampicillin and incubated 16-18 hours at 37ºC.
After the incubation period, 2 colonies were chosen from the plate with a sterile toothpick
and placed in 3ml of LB with ampicillin. This was incubated at 37ºC for 8 hours. 50.0μl
of the 3ml culture was added to 50ml of LB with ampicillin and placed in the shaking
incubator at 37ºC and 220 rpm for 16-18 hours. A QIAGEN HiSpeed® Plasmid Midi Kit
was used to purify the receptor following the method described above.
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2.14 Restriction enzyme digest
Purified TOPO plasmids containing the 1.7 kb ACPP promoter insert of each
species were digested using a double restriction enzyme digest. In a 40.0µl reaction: 23.6
µl sterile Molecular Biology grade water, 1X Multi-Core Restriction Enzyme Buffer, 4μg
Acetylated BSA (10µg/µl), 10.0 µg TOPO vector (1.0 µg/µl), 10 units restriction enzyme
Sac I (10U/µl), and 1.0 unit restriction enzyme Acc 651 (10U/µl). This reaction was
incubated at 37°C for 2 hours, and then deactivated at 65°C for 15 minutes. The TOPO
digest was run on a 0.8% Agarose gel made with 1X SB and ethidium bromide at 125
Volts for 35-40 minutes. After running the gel to separate the 1.7 kb ACPP insert from
the 4 kb Topo vector, the 1.7 kb insert was manually cut out of the gel. It was purified
using Promega Wizard®SV Gel and PCR Clean-up System column purification. The
resulting product was run on a 1% agarose gel stained with ethidium bromide at 150
Volts for 30 minutes along with Fisher Low Range DNA Ladder to determine the
quantity of ACPP insert after purification. Purified pGL4.10 [luc2] was also purified
using a double restriction enzyme digest. In a 20.0 µl reaction: 11.8 µl sterile Molecular
Biology grade water, 1X Multi-Core Restriction Enzyme Buffer, 2 µg Acetylated BSA,
5.0 µg pGL4.10 [luc2], 0.5 units restriction enzyme Sac 1 (10U/µl), and 0.5 µnits
restriction enzyme Acc 651 (10U/µl). This reaction was incubated at 37°C for 2 hours and
deactivated at 65°C for 15 minutes.
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2.15 Calf intestinal alkaline phosphatase (CIAP) to remove 5’ phosphates
To catalyze the hydrolysis of 5` phosphates from the digested pGL4.10 [luc2],
calf intestinal alkaline phosphatase (CIAP; Promega) was added directly to the digest
reaction. The addition of CIAP enhances ligation efficiency by preventing the digested
vector from ligating back together before the insert is in place. Into the 20 µl digest
reaction: CIAP 1X Reaction Buffer, 0.05 units CIAP, and sterile Molecular Biology
grade water up to 50.0 µl. This reaction was incubated at 37°C for 30 minutes, another
aliquot of 0.05 U CIAP was added to the reaction, and an additional 30 minute incubation
at 37°C was performed before adding 300.0 µl of CIAP Stop Buffer: 10mM Tris-HCL
(pH 7.5), 1mM EDTA (pH7.5), 200mM NaCl, 0.5% SDS. The entire reaction was
purified using Promega Wizard Clean-up System column purification. 4.0 µl of the
resulting product was run on a 1% Agarose gel made with 1X SB and loaded with 3.0 µl
loading buffer along with the Fisher Low Range DNA Ladder in order to estimate
concentration after purification.

2.16 Ligation of insert into luciferase reporter vector
The digested and purified ACPP insert of each hominoid species and macaque
were individually cloned into the digested and purified pGL4.10 [luc2] by joining the 5`
overhang of one molecule with the 3` overhang of a corresponding strand. This was
performed through the use of T4 DNA ligase (Promega). For each species, the
recommended 1:1 molar ratio of vector DNA to insert DNA was assembled as well as 1.0
µl variations of this ratio in order to optimize the ligation conditions for each individual
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reaction. In a 10 µl reaction: 100 ng pGL4.10 [luc2] DNA, 17 ng ACPP insert DNA, 1X
Ligase Buffer, 1.0 µnit T4 DNA Ligase, up to 10.0 µl Molecular Biology grade water. A
reaction containing only pGL4.10 [luc2] and no insert was also set up to control for
undigested vector backbone. The reactions were ligated at room temperature for 3 hours
or at 4°C overnight. After the incubation time, the entire 10.0 µl ligation reaction was
added to 200.0 µl chemically competent E. coli and the plasmids were transformed as
described above. After transforming the E.coli, the 20.0 µl, 50.0 µl, 100.0 µl, and 200.0
µl were plated on pre-warmed LB plates with ampicillin. The plates were incubated at
37°C for 16-18 hours. Approximately 8-16 colonies from each plate were then picked
into 1 ml of LB broth with ampicillin in a 96 well culture plate as described above.
Screening for the presence of the ACPP insert was performed with vector specific and
gene specific primers as described above. After choosing a culture that appears to contain
the insert, a 50 ml of LB with ampicillin was inoculated with 50.0 µl of the 1 ml culture
and placed in the shaking incubator at 37° C for 16-18 hours. The plasmids were purified
using the QIAGEN Hi-Speed Midi-Prep 50 ml protocol for hi-copy plasmids as described
above. They were sequenced using vector primers flanking the insert as well as ACPP
specific primers to ensure the correct ligation of the insert and check for cloning errors.

2.17 Thawing and recovering human cells
The prostate cancer cell line, LNCaP, clone FGC (ATCC: CRL-1740), was used
in all cell culture experiments. 10 ml of complete medium containing 10% Fetal Bovine
Serum (FBS; Hyclone) and antibiotic was prepared by adding 9 ml of RPMI 1640
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medium (2mM L-glutamine; ATCC), 1 ml FBS, and 100 µl 100x Penicillin/Streptomycin
in a sterile 15 ml conical tube (Falcon) and warmed to 37°C in a water bath. The frozen
LNCaP cells were transferred to a 37°C water bath and continuously agitated until
thawed. The vial was wiped with 70% ethanol before placing in a sterile tissue culture
hood and opening. The cell suspension was then transferred to a 15 ml conical tube
containing 2 ml of the complete medium with FBS. It was centrifuged for 10 minutes at
1000 rpm. After removing from the centrifuge, the supernatant was removed and placed
in a 25 cm2 tissue culture flask (Corning Cell Bind Surface) as a back-up. The cell pellet
was resuspended in 1 ml of the complete medium with FBS and transferred to a 25 cm2
tissue culture flask with 4 ml of complete medium. The flasks were placed in a
humidified 37°C, 5% CO2 incubator for optimal cell growth. The cells were observed
after 24 hours to ensure attachment of cells to the flask surface. They were observed daily
to look for changes in growth and an increase in the acidity of the medium indicated by a
shift in color from red to yellow. The medium was changed every 3-4 days as needed by
removing and discarding the old medium into a small beaker containing 10% bleach and
replacing it with pre-warmed, freshly prepared complete medium with FBS.

2.18 Trypsinizing and subculturing human cells
When the cells achieved ~80-90% confluency, they were subcultured into 4 new
flasks. The old medium was removed with a sterile pipette and discarded into 10%
bleach. The cells were washed in 1 ml of 37°C Hank’s Buffered Salt Solution (HBSS;
Fisher) to remove residual FBS. This was removed immediately and 1 ml of 37°C trypsin
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(Sigma) was added to cover the cell layer. The flask was placed in the 37°C incubator for
3-4 minutes to allow complete detachment of cells from the flask surface. The cells were
also observed under an inverted microscope to ensure detachment had occurred. 3 ml of
37°C complete medium was added to the trypsinized cells and they were rinsed 8-10
times to dislodge remaining cells and cell clumps. 1 ml of this 4 ml cell suspension was
added to 4 new 25 cm2 tissue culture flasks containing 4 ml of complete medium. The
flasks were wiped with 70% ethanol and again placed in the 37°C, 5% CO2 incubator.

2.19 Freezing human cells
Sterile freezing medium was prepared (20 ml) containing 10% FBS and 10%
dimethyl sulfoxide (DMSO). In a 50 ml conical tube: 16 ml RPMI 1640 medium (2mM
L-glutamine), 2 ml FBS, 2 ml DMSO. Once the cells achieved 80-90% confluency, the
old medium was removed and discarded into 10% bleach. The cells were washed by
adding 1 ml of 37°C HBSS, which was immediately removed. 1 ml of 37°C trypsin was
added to the cell layer and the flask was incubated at 37°C for 3-4 minutes to ensure
detachment of cells. 2 ml of 37°C compete medium was added to the flask and the cell
suspension was transferred into a sterile 15 ml conical tube. The tube was centrifuged for
5 minutes at 1500 rpm. The supernatant was removed and the pellet resuspended in 3 ml
of 4°C freezing medium. 1 ml of the cell suspension was aliquoted into 2 ml cryovials
and placed in an isopropanol slow freezing apparatus for 1 hour in the -80°C freezer. The
vials were then transferred to a liquid nitrogen storage freezer for long-term storage.
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2.20 Counting cells and seeding 12 well plates
Cells were washed with 37°C HBSS which was immediately removed and
discarded. 1 ml of 37°C trypsin was added to the cell monolayer to detach the cells. The
flask was placed in the 37°C incubator for 3-4 minutes. 3 ml of complete medium was
added to the flask and cell suspension was pipetted up and down to break up cell clumps.
In a separate test tube, 500 µl Trypan Blue (Sigma), 300 µl HBSS, and 200 µl of the cell
suspension were mixed (cell suspension diluted 1:5). Approximately 30 µl of the mixture
was removed to dispense in the hemocytometer. A small amount of the suspension was
placed under the coverslip on one side of the hemocytometer and allowed to fill the
chamber. This was repeated on the other side. The number of viable (bright) cells was
counted in 5 squares from each side of the hemocytometer. The average number of
squares was calculated and the viable number of cells calculated with the following
formula:
Viable cells/ml = average # cells per square X 5 (dilution factor) X 104 (volume
correction)
To plate 200,000 cells per well in a 12 well plate (Corning CellBind® Surface), the
following formula was used:
200,000 cells ÷ # viable cells per ml = # ml of cell suspension to be added to each well
Complete medium up to 1 ml was added to make the final volume in each well 1 ml.

26

2.21 Transfection optimization with GFP
The LNCaP cells were transfected with a plasmid containing Green Fluorescent
Protein (GFP) (GFP-pFLAG cmv 5a/DH5α) to optimize transfection efficiency using
FuGENE HD transfection reagent (Roche). This construct was a generous gift from Dr.
P. Auron, Duquesne University. A 12-well plate (Corning CellBind®) was seeded with
200,000 cells per well. RPMI1640 medium (no FBS or antibiotic) was used as a diluent
to prepare DNA with a concentration of 2 µg per 100 µl. 100 µl of the mixture was
placed in 6 separate tubes. To these tubes, 0µl, 3µl, 4µl, 5µl, 6µl, and 8µl of FuGENE
transfection reagent was added to the tubes for a 0:2, 3:2, 4:2, 5:2, 6:2, and 8:2 ratio of
FuGENE to DNA, respectively. After a 15 minute incubation, 48 µl was added to ½ of
the wells by pipetting in a drop-wise manner to ensure even application to the cells. After
30 minutes, 48 µl was added to the remaining 6 wells of cells. The plates were placed in
the 37ºC, 5%CO2 incubator for 48 hours before viewing the cells with an inverted
confocal microscope.

2.22 Transfection pGL4.10 constructs
It was determined through optimization with the GFP plasmid that a 3:2 ratio of
FuGENE to DNA and a 30 minute incubation time was most effective in transfection of
the LNCaP cells. 12-well plates (Corning CellBind®) were seeded with 200,000 cells per
well. The concentration of the pGL4.10 [luc2] constructs containing the ACPP promoter
of each hominoid species was determined by UV spectroscopy. Separate cocktails for
each species and an empty vector were set up to contain1.0µg of pGL4.10 construct (or
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empty vector for a control), 0.1 µg of pGL4.70 (Renilla), 1.5 µl FuGENE transfection
reagent, and up to 1 ml of complete medium per well. For experiments with androgen
receptor cotransfection, 0.2 µg/well of androgen receptor was also added to the cocktail
before bringing final volume to 1.0 ml per well. The cocktails were incubated at room
temperature for 30 minutes before 50.0 µl of the cocktail was added in a drop-wise
manner to each appropriate well on the 12-well plate. The plates were then placed back in
the 37ºC, 5% CO2 incubator.

2.23 Addition of R1881
Methytrienolone (R1881) (PerkinElmer Life Sciences, Inc), a synthetic androgen,
was added to select 12-well plates in order to test the effect of androgen on gene
expression. To make 10 mM stocks, 5 mg of R1881 was diluted in 1.76 ml 100% ethanol.
100μM working stocks of R1881 were made by adding 10μl of the 10 mM stock to
1000μl of ethanol. To apply a 10 nM treatment to selected wells of the 12-well plate, the
old medium was removed from each well and discarded into 10% bleach. 1 μl of 100 μM
R1881 was added to 10ml of complete medium and 1 ml of this added to select wells. For
a vehicle control, 1 μl of 100% ethanol was added to 10 ml of complete medium and 1 ml
of this was added to other remaining wells. The addition of androgen was performed 24
hours after transfection.
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2.24 Dual-luciferase reporter assay
The cells of the 12-well plate were passively lysed by first removing the old
medium and washing the monolayer with 250 μl of 1X Phosphate Buffered Saline
(PBS;Fisher). The PBS wash was removed and 250 μl of 1X Passive Lysis Buffer (PLB)
(Promega) was added to each well. The plates were gently rocked for 15 minutes to
ensure complete lysis of the cells. From each well of the 12-well plate, 20 μl of the
resulting lysate was transferred to a well in a 96 well plate where the reporter assay was
performed. 20 μl of PLB was also placed in one well of the plate to control for
background luminescence. Luciferase Assay Reagent II (LAR II) and Stop & Glo®
Reagent were prepared using the protocol and reagents provided in the Dual-Luciferase®
Reporter Assay System kit (Promega). Excess reagent was aliquoted into 1.5 ml screw
cap tubes (for LAR II) and 1.5 ml siliconized polypropylene tubes (for Stop & Glo®) for
storage. The reagents were brought to room temperature before use in the assay. The 96
well plate and the reagents were placed into the auto-injecting Veritas microplate
luminometer version 1.1 (Turner Biosystems). The luminometer first dispenses 100 μl of
LAR II to measure the firefly luciferase activity, then dispenses 100 μl of the Stop & Glo
reagent to quench the firefly luciferase activity and measure Renilla luciferase activity.
After the luminescence was recorded, the ratio of relative luminescence of firefly
luciferase to Renilla luciferase was calculated. This was done by subtracting the firefly
luminescence recorded from the PLB from the firefly luminescence recorded in the
sample in question and dividing this number by the Renilla luminescence recorded in the
plain PLB subtracted from the Renilla luminescence recorded in the same sample well.
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This relative ratio was compared across treatments and hominoid species to determine
levels of expression. For all experiments, one assay per transfection was performed.
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Chapter 3
Results
3.1 Characterization of ACPP promoter
The 2.2 kb region upstream of ACPP was viewed through the UCSC genome
browser using the March 2006 Human Assembly. This region is located on chromosome
3 in position 133,517,148 to 133,519,347. General characterization of the putative
promoter was made by means of various tracks available to customize the view (Figure
2). A number of points were noted from this first examination. The first exon of the gene
contains coding sequence. The RefSeq Genes and Switchgear TSS tracks illustrate that
there is not evidence of an additional exon upstream of the first annotated exon. The
presence of elements related to transcription, such as TATA at -27, CAAT at -40, and
ATG at +51 (Shan et al. 1997), are further indicative that the predicted first exon is a
coding exon. There are no CpG islands predicted in the region. This is of note because
promoter regions are often GC rich as to be involved with transcriptional regulation
through methylation. Finally, there are several short interspersed nuclear elements
(SINEs) in the promoter taking up over 51% of the 2 kb directly upstream from the
transcription start site. This is higher than the genome average and much higher than
most promoter regions (Venter et al., 2001).
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Figure 2: Overview of ACPP promoter region in UCSC genome browser. A 2.2 kb
region of the ACPP promoter, located on chromosome 3 at position 133,517,148 to
133,519,347, as viewed in the UCSC genome browser (Kent et al., 2002). The 1.7 kb
area included in the pGL4.10 [luc2] constructs is displayed (“ACPP construct”).
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3.2 Conservation across species
To predict functionally important regions of the promoter that may play a role in
the regulation of ACPP gene expression, the UCSC genome browser was used to explore
areas of conservation across a number of species (Figure 3). The same chromosome
region and position were used as in previous analyses. A number of peaks of
conservation were discovered in the 1.5 kb region upstream of transcription and in the
area immediately downstream of the first exon. For 5 of the highest peaks, 4 upstream
and 1 downstream of transcription start, the human sequence was obtained from the
browser and put through a suite of transcription factor binding site prediction programs
(TFSEARCH, MatInspector, TESS). The results of the transcription factor binding site
predictions varied between the programs, likely with a large number of false positive
results. In order to increase the likelihood of identifying true positive results, the
transcription factors that were predicted in at least 2 of the 3 programs are shown in Table
2.
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Figure 3: Peaks of high conservation are located in the ACPP promoter. Within the
ACPP region inserted into the pGL4.10 [luc2] construct, there are a number of peaks of
high conservation. Conserved elements 1-5 were used in transcription factor binding site
prediction.
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Conserved
element
1
2
3
4
5

Position
chr3: 133518235-133518308
chr3: 133518721-133518804
chr3: 133518101-133518117
chr3: 133518884-133518926
chr3: 133519226-133519263

Predicted TFBS
cap, HSF, Bcd, ADR1, GCN4, Ik-2, CRE-Bp
MZF1, RoRalp, CdxA. Nkx-2
c-Myb
Nkx-2, S8, ADR1, Dfd
HSF, cap, C/EBPb, Oct-1, Dfd, SRY, Nkx-2, HSF2

Table 2: Transcription factor binding sites predicted in conserved elements in the
ACPP promoter. Input of the sequence of 5 conserved elements into 3 separate
transcription factor binding site prediction programs produced a large number of results.
Transcription factor binding sites that were predicted in at least 2 of the 3 programs are
summarized in the table.
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3.3 Location of previously identified TFBS
In order to visualize previously predicted transcription factor binding sites and
experimentally established regulatory regions of the ACPP promoter, the UCSC genome
browser was again used to plot the location of these elements (Figure 4). Included in the
plot are putative Androgen Response Elements (AREs) (Shan et al., 2003), DNAse
footprinting areas (Shan et al., 1997), and areas demonstrated to be important for
upregulation or downregulation of expression (Zelivianski et al., 2002). These elements
are mainly located upstream of transcription start, however two AREs are located
immediately following the first exon and one DNAse footprinting area is located past
transcription start in the 5’ untranslated region.
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Figure 4: Elements important to transcriptional regulation of ACPP in human have
been previously reported. Others have indentified elements that may be involved in the
transcriptional regulation of ACPP in humans. These elements include regions of
upregulation and downregulation in vitro (Zelivianski et al., 2002), DNA footprinting
regions (Shan et al.,1997), and androgen response elements (ARE) (Shan et al., 2003).
The location of these elements relative to the area covered by the ACPP construct are
plotted.
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3.4 Optimization of transfection methods with GFP vector
Optimization of transfection methods in the prostate cancer cell line, LNCaP, was
performed by transfecting a vector containing green fluorescent protein (GFP) into the
cell line using varying ratios of µl of FuGENE transfection reagent to µg of vector DNA.
These ratios were 0:2, 3:2, 4:2, 5:2, 6:2, and 8:2. The incubation time for the transfection
complex was also optimized, adding the complex to the ½ of the cells after a 15 minute
incubation, and adding the complex after a 30 minute incubation for the remaining ½ of
the cells. After 48 hours and 72 hours, the same 12-well plate was viewed using an
inverted fluorescent microscope and multiple comparisons were made of cell number and
fluorescence among the many treatments. The different ratios of transfection reagent to
DNA were compared to each other at the 48 hour observation, the 72 hour observation,
and between the 48 and 72 hour observations. Similarly, the incubation times of the
transfection complex were compared between the 15 minute and 30 minute incubation
times at the 48 hour observation, the 72 hour observation, and between the 48 hour and
72 hour observation. While no formal statistical analyses were made, qualitative and
quantitative observations as well as manual counting of cells provided some general
results (Figure 5). The transfection was successful under all experimental conditions;
however the lowest non-zero ratios of FuGENE transfection complex to vector DNA
produced the greatest fluorescence after both 48 and 72 hours post-transfection. It was
also established that 72 hours post-transfection produced the greatest fluorescence
overall, with approximately 25% transfection efficiency. It was therefore determined that
future transfection experiments using the LNCaP cell line would be performed with a 3:2
FuGENE to DNA ratio and observed 72 hours after transfection.
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a

b

Figure 5: Optimization of Transfection Methods in the LNCaP Cell Line with a
GFP Containing Vector. The transfection optimization experiment was designed to
compare ratios of transfection reagent to DNA, as well as examine incubation time of the
transfection complex before adding it to the cells. The time after transfection required for
optimal fluorescence was also noted. It was concluded that the lower levels of
transfection reagent to DNA, a 30 minute transfection complex incubation time, and a 72
hour post transfection period before observing fluorescence were the optimal conditions
in the LNCaP cell line. Shown is the same well of cells viewed with normal light (a) and
with a fluorescent light source (b) under optimal conditions: 3:2 ratio of FuGENE to
DNA, 30 minute incubation, 72 hours post-transfection.
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3.5 Human ACPP promoter drives expression in LNCaP cells
To determine if the pGL4.10 [luc2] construct containing the human ACPP
promoter (-1593 to +117) was able to drive transcription in vitro in the LNCaP cell line,
the relative luminescence produced by the human construct was compared to the relative
luminescence produced by the empty vector. The human construct and empty vector were
transfected in duplicate into cells in alternating wells of the same 12-well tissue culture
plate using the lipid-based transfection reagent, FuGene. pGL4.10 [hRluc] was also
transfected to control for transfection efficiency. The LNCaP prostate cancer cell line is
known to be stimulated by androgen and therefore synthetic androgen, methytrienolone
(R1881), was applied (10nM) to select cells in the plate. An ethanol control was used to
determine if the vehicle was affecting transcription levels. Charcoal-stripped FBS
(HyClone) was used to make the complete medium that was applied during the androgen
treatments to ensure that excess androgen was not introduced through use of FBS. In all
treatments, the human promoter was able to drive transcription ~5-fold more effectively
than the empty vector under the same conditions (Figure 6). This difference was
significant in the 10 nM R1881 treatment (p=0.0076). In the no treatment transfections
(p=0.1709) and vehicle control transfections (p=0.2147), the difference was not
significant between the human and empty constructs.
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(Firefly/Renilla)
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in LNCaP Cells
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Figure 6: The human ACPP promoter drives transcription in the in vitro system. The
pGL4.10 [luc2] construct containing the human ACPP promoter was able to drive
transcription to a higher level than the empty vector in the LNCaP cell line. The
transfection of the human construct and empty vector was carried out under three
experimental conditions. Relative luminescence was used to assess expression driven by
the promoter. In all cases, the expression driven by the human promoter was higher than
the empty vector, and this was significant in the 10 nM R1881 treatment. T-test: no
treatment (p=0.1709), 10nM R1881 (p=0.0076), EtOH (p=0.2147) n=2.
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3.6 Hominoid species vary in transcription
The difference in expression between the ACPP promoters of the hominoids and
macaque was analyzed by comparing the relative luminescence of each in an in vitro
system (Figure 7). The pGL4.10 [luc2] constructs containing 1.7 kb of the upstream
promoter of human, bonobo, gorilla, orangutan, gibbon, or macaque were transfected into
the LNCaP cells. The pGL4.70 [hRluc] vector producing Renilla luciferase was also
cotransfected to control for transfection efficiency. These transfections were performed in
quadruplicate (n=4). 72 hours post-transfection, the dual luciferase reporter assay was
completed and the relative luminescence measured in a luminometer. The means of the
samples were significantly different (ANOVA; p<0.0001), and multiple pairwise
comparisons using Tukey’s post test were also significant (Table 3). These include a
significant difference in expression between bonobo and human (p<0.001), gorilla
(p<0.001), orangutan (p<0.001), and gibbon (p<0.001). There was a significant
difference between gorilla and human (p<0.001), orangutan (p<0.01), gibbon (p<0.05),
and macaque (p<0.001). The difference between human and gibbon (p<0.05) and
macaque (p<0.001) was also significant.
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Figure 7: Differential expression by the ACPP promoter exists between the
hominoids. Levels of relative luminescence driven by the ACPP promoter of human,
bonobo, gorilla, orangutan, gibbon, and macaque were compared under normal
conditions with no application of R1881 or cotransfection of hAR receptor. There is a
significant difference in expression between the species (ANOVA; p<0.0001; n=4)

Table 3: Tukey’s Multiple Comparison Post-Tests (No Treatment)
Human
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

Human

Bonobo

Gorilla

Orangutan

Gibbon

p<0.001
p<0.001
p>0.05
p<0.05
p<0.001

p<0.001
p<0.001
p<0.001
p>0.05

p<0.01
p<0.05
p<0.001

p>0.05
p<0.001

p<0.001
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3.7 Hominoid species vary in transcription with androgen
R1881 was applied to the LNCaP cells after transfection to determine if the
expression of ACPP is in part affected by androgen (Figure 8). The pGL4.10 [luc 2]
constructs containing the ACPP promoter of the hominoids and macaque were
transfected in the LNCaP cells in quadruplicate (n=4), along with the pGL4.10 [hRluc]
vector. 24 hours after transfection, 10 nM R1881 was applied to the cells in new medium
containing charcoal-stripped FBS. The luciferase reporter assay was performed 72 hours
after transfection and the levels of relative luminescence were measures in a
luminometer. Means of species were significantly different (ANOVA; p<0.001) as were
many of the pairwise comparisons (Tukey’s post-test). These include a significant
difference in expression between human and orangutan (p<0.05), gibbon (p<0.01), and
macaque (p<0.05). There were also significant differences in expression between and
bonobo and other species: gorilla (p<0.001), orangutan (p<0.01), gibbon (p<0.001), and
macaque (p<0.01). Finally, gorilla was significantly different than orangutan (p<0.001),
gibbon (p<0.01) and macaque (p<0.001) (Table 4).
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Figure 8: Differential expression by the ACPP promoter exists between the
hominoids when treated with 10nM R1881. Levels of relative luminescence driven by
the ACPP promoter of human, bonobo, gorilla, orangutan, gibbon, and macaque were
compared after application of 10 nM R1881. There is a significant difference in
expression between the species (ANOVA; p<0.001; n=4).

Table 4: Tukey’s Multiple Comparison Post-Tests (10 nM R1881)
Human
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

Human

Bonobo

Gorilla

Orangutan

Gibbon

p>0.05
p<0.001
p<0.05
p<0.01
p<0.05

p<0.001
p<0.01
p<0.001
p<0.01

p<0.001
p<0.01
p<0.001

p>0.05
p>0.05

p>0.05
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3.8 Human ACPP promoter drives expression with androgen receptor and
androgen
The effect on expression of cotransfecting the hAR into the LNCaP cells was
examined after differences in expression were found to exist among hominoids with the
application of R1881. This was first tested in human by cotransfecting 0.2μg hAR with
the transfection of the pGL4.10 [luc2] construct and pGL4.70 [hRluc] control vector to
ensure that expression was greater than the empty vector. Also, 1nM or 10nM R1881 was
applied 24 hours after transfection for certain experimental conditions. Both experimental
conditions were performed in triplicate. After comparing expression levels to the empty
pGL4.10 [luc2] vector, it was determined that the pGL4.10 [luc2] construct containing
1.7 kb of the human ACPP promoter was able to drive transcription to significantly
higher levels than the empty vector under 1nM R1881 (p=0.0094) and 10nM
R1881(p=0.0238) experimental conditions (Figure 9). There was not a significant
difference between the human ACPP construct under 1 nM versus 10 nM R1881
(p=0.3422).
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Figure 9: The human promoter drives transcription in the presence of androgen
after cotransfection with androgen receptor. The pGL4.10 [luc2] construct containing
the human ACPP promoter was able to drive transcription to a higher level than the
empty vector in the LNCaP cell line after cotransfection with hAR and addition of
R1881. The transfection of the human construct and empty vector was carried out under
two experimental conditions. Relative luminescence was used to assess expression driven
by the promoter. In both cases, the expression driven by the human promoter was higher
than the empty vector, and this was significant in the 1 nM R1881(p=0.0093) and 10 nM
R1881 (p=0.0238) treatments (n=3).
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3.9 Hominoid species vary in transcription with androgen receptor and
androgen
To further examine the effect of androgen on ACPP expression in hominoids and
macaque, hAR was cotransfected into the LNCaP cells at the same time the pGL4.10
[luc2] constructs containing the hominoid promoter and pGL4.20 [hRluc] vector were
transfected. hAR is the receptor that functions to bind the androgen molecule. A final
concentration of10nM R1881 was also applied to the cells in charcoal-stripped medium
24 hours after transfection. The relative luminescence of all species was compared 72
hours after transfection. The means of the samples were significantly different (ANOVA;
p<0.001) and multiple pairwise comparisons that were also significant (Tukey’s post-test)
(Figure 10). These include significant differences between human and bonobo (p<0.05),
gorilla (p<0.001), and gibbon (p<0.05). There is also a significant difference between
bonobo and gorilla (p<0.001), orangutan (p<0.01), gibbon (p<0.001), and macaque
(p<0.001). Finally, a pairwise comparison finds gorilla expression significantly different
than orangutan (p<0.001) and macaque (p<0.01) (Table 5).
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Figure 10: Differential expression by the ACPP promoter exists between the
hominoids after cotransfection with 0.2µg hAR and addition of 10nM R1881. Levels
of relative luminescence driven by the ACPP promoter of human, bonobo, gorilla,
orangutan, gibbon, and macaque were compared after cotransfecting with 0.2μg hAR and
application of 10 nM application of R1881. There is a significant difference in expression
between the species (ANOVA; p<0.001; n=4).

Table 5: Tukey’s Multiple Comparison Post-Tests (0.2 μg hAR + 10 nM R1881)
Human
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

Human

Bonobo

Gorilla

Orangutan

Gibbon

p<0.05
p<0.001
p>0.05
p<0.05
p>0.05

p<0.001
p<0.01
p<0.001
p<0.001

p<0.001
p>0.05
p<0.01

p>0.05
p>0.05

p>0.05
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3.10 Androgen receptor increases expression in some species
To determine if hAR is responsible for changes in expression within species after
application of 10nM R1881, the relative luminescence of the 10nM treatment was
compared to the relative luminescence of the 0.2µg hAR + 10nM R1881 treatment. A ttest was performed on the samples from each treatment (n=4) and it was determined that
the expression driven by the ACPP promoter was significantly higher with the 0.2µg
hAR+ 10nM R1881 treatment than with the 10nM R1881 alone in certain species (Figure
11). These species include bonobo (p=0.007), gorilla (p=0.007), and orangutan
(p=0.0291). The other species did not exhibit the same trend of increased expression with
cotransfection of hAR and expression was not significantly different between the
treatments: human (p=0.9672), gibbon (p=0.0811), and macaque (p=0.2694).
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Figure 11: Bonobo, gorilla, and orangutan show significantly increased expression
by the ACPP promoter with the addition of 0.2µg of hAR and 10nM R1881 than
with 10nM R1881 alone. The within species relative luminescence of human, bonobo,
gorilla, orangutan, gibbon, and macaque were compared between the 10nM R1881 and
0.2µg + 10nM R1881 experimental treatments. Bonobo (t-test; p=0.0070), gorilla (t-test;
p=0.0070), and orangutan (t-test; p=0.0291) showed significantly increased expression by
the ACPP promoter when 0.2µg hAR was cotransfected and cells were treated with
10nM R1881 than with the treatment with 10nM R1881 alone.
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3.11 Human ACPP relative luminescence is variable
Because much week-to-week variation in relative luminescence ratios of the
human ACPP construct was apparent after examination of multiple treatments,
comparisons of the ratios were made based on treatment type and day of transfection
(Figure 12). After graphing these values, it was determined that the relative luminescence
ratios from all experimental conditions performed in the first week were higher (1.5 to 5
times higher) and had larger standard errors than the following human transfection. The
levels of relative luminescence and measures of error for the second and third
transfections of the human construct were more consistent with levels of luminescence
and error seen in transfections of the other hominoid constructs.
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Figure 12: Relative luminescence ratios by the human ACPP promoter were
variable. Luminescence ratios differ by day of transfection. Transfections performed on
the same day are indicated by the same graph pattern. The first transfections performed
(white) are much higher with larger errors than transfections performed second (stripe) or
third (black).
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3.12 Nucleotide variation exists between species
After finding significant differences in expression of ACPP in bonobo and gorilla,
the variation in nucleotide sequence between these species and human were compared to
identify changes that may be leading to differential expression. The sequence of the 1.7
kb region of ACPP promoter contained in the pGL4.10 [luc2] constructs of human and
bonobo were aligned in Mega (Tamura et al., 2007) and variable sites were identified.
These sequences were then put into TFSEARCH to determine predicted transcription
factor binding sites for the region. In 22 nucleotide differences between human and
bonobo, there were 14 changes that occurred in only the chimpanzee and bonobo lineage,
with 9 of those changes exclusive to bonobo. The other differences between human and
bonobo were shared by all of the apes. The nucleotide changes in the chimpanzee and
bonobo lineage led to a gain of 11 predicted transcription factor binding sites that differed
from human, with 9 of those being specific to bonobo (Table 6). The same comparison
was made between the 1.7 kb region of human and gorilla. In the comparison between
human and gorilla, 31 variable nucleotides were found. Of these, 17 were exclusive to
gorilla while the additional changes were shared with other apes. The 17 gorilla-specific
nucleotide changes resulted in a loss of 12 putative transcription factor binding sites that
are predicted in human (Table 7).
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Table 6: Human and Bonobo: Differences in Predicted Transcription Factor
Binding Sites
Species

Sequence

Exclusive TFBS

Human

TCTGCCATTATGATAGAAATA

NIT2,Skn-1,Nkx-2

Bonobo

TCTGCCATTAGGATAGAAATA

GATA-2

Human

AGTTCCATCAGTCTGGATCGC
AGTTCCATCAATCTGGATCGC

Human

TTTTTGTTGTTGTTTGTTTGT

HNF-3b, HFH-2

Bonobo

TTTTTGTTGTCGTTTGTTTGT

Human

GGCATGTGCCACCACGCCAGG

Bonobo

GGCATGTGCCCCCACGCCAGG

Human

TGTATTTTTAGTAGAGATGGG

Bonobo

TGTATTTTTATTAGAGATGGG

Human

GATCTGCCCACCTCGGCCTCC

Bonobo

GATCTGCCCATCTCAGCCTCC

Position
193

all apes
244

CDP CR, CdxA,
GATA-1

Bonobo

Occurrence

Bonobo only
500
Chimp & Bonobo
654

ADR1

Bonobo only

Brn-2, Hb

Chimp & Bonobo

GATA-1, GATA-2, cap

Bonobo only

Bonobo only

690

757,761

Human

GCTGGGATTACAGACATGAGC

Bonobo

GCTGGGATTATAGACATGAGC

MATalp

784

Human

TTCAGTCCTATAACTTTGGAC

CdxA

Bonobo

TTCAGTCCTACAACTTTGGAC

Human

TAAAGAAAAGATAAAAGTAAA

Bonobo

TAAAGAAAAGCTAAAAGTAAA

Human

CAAGGCAGGCGGATCATGCGG

Bonobo

CAAGGCAGGCAGATCATGCGG

966
all apes

No difference

1081
Chimp & Bonobo

No difference

1157
Chimp & Bonobo

Human

TGCAGTGAGCTGAGATTGTGC

Ap-4

Bonobo

TGCAGTGAGCCGAGATTGTGC

GATA-2

Human

GTGCCACTGTGCTCCAGCCTG

No difference

Bonobo

GTGCCACTGTCCTCCAGCCTG

1329
all apes
1345
all apes

Human

TCCAGCCTGGATGACAGAGCA

Skn-1

Bonobo

TCCAGCCTGGGTGACAGAGCA

AP-1

Human

ATGACAGAGCAAGACTCTGTCT

No difference

Bonobo

ATGACAGAGAGAGACTCTGTCT

1358
all apes
1367
Bonobo only
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(Table 6: Continued)
Species

Sequence

Exclusive TFBS

Human

GCAAGACTCTGTCTCAAAAAAA

Bonobo

GCAAGACTCTCACTCAAAAAAA

cap

Human

AAAAAAAAAACAAAAAACAAA

BR-C Z

Bonobo

AAAAAAAAAAAAAAAAACAAA

Human

TGAAAACAAGGATAGAAATGT

Bonobo

TGAAAACAAGAATAGAAATGT

Human

CAGCTTTCCCCGCTCTTGGCC

Bonobo

CAGCTTTCCCTGCTCTTGGCC

Human

AACTTTACTACTTATGAGTGT

Bonobo

AACTTTACTATTTATGAGTGT

Occurrence

Position
1376

Bonobo only
1394
all apes

No difference

1416
all apes

MZF1, ADR1

1478
Chimp & Bonobo
1595

BR-C Z

all apes

Table 6: The sequences of human and bonobo were aligned and variable nucleotides
between the species were noted. The variable nucleotide plus 10 nucleotides before and
after were put into the TFSEARCH transcription factor binding site prediction program.
The predicted transcription factors that are exclusive to one species are noted on the same
line as that species’ nucleotide sequence. The occurrence of that change in one or more
species is also noted. There were 22 nucleotide changes between human and bonobo, 9 of
which were specific to bonobo, resulting in a gain of 9 more transcription factor binding
sites than what was predicted in human.

56

Table 7: Human and Gorilla: Differences in Predicted Transcription Factor Binding
Sites
Species

Sequence

TFBS-TFSearch

Occurrence

Human

GCAATGTACCAGGAAACAGGTTG

Gorilla

GCAATGTACCATGAAACAGGTTG

HSF

Human

GTAAACCATTGTTCTCCCTCT

Sox-5

Gorilla

GTAAACCATTTTTCTCCCTCT

dl, CdxA

Human

TCTGCCATTATGATAGAAATA

NIT2, Skn-1, Nkx-2

Gorilla

TCTGCCATTAGGATAGAAATA

GATA-2

all apes

Gorilla only

Position
69

Gorilla only

Human

TCTGCCCCCAAATCTTGCAAA

Gorilla

TCTGCCCCCACATCTTGCAAA

GATA-1

Human

TCTGGATCGCCTTTTGTAGTG

TATA

Gorilla

TCTGGATCGCTTTTTGTAGTG

Human

AGTGTCCCCAGTGAGATCATA

Gorilla

AGTGTCCCCAATGAGATCATA

Human

GTAATGTCCAATTGTCTTAAG

Gorilla

GTAATGTCCAGTTGTCTTAAG

Human

GTTTGTTT____TGCTGTGTTTTGAGAT

Gorilla

GTTTGTTTTGTTTGTTTTGTTTTGAGAT

95
Gorilla only
113

149

255
Gorilla only
272

NF-Y

G, O, Gib, M
449

c-Myb

Gorilla only

HFH-2, HNF-3b, BR-C Z

G, O, Gib, M

513, 515

Human

CAGTGGCACAATCTCGGCTCA

GATA-1, GATA-2, GATA-3

Gorilla

CAGTGGCACAGTCTCAGCTCA

cap

568, 573
Gorilla only

Human

ACTATAGGCATGTGCCACCA

USF

Gorilla

ACTATAGGCAGGTGCCACCA

Sn, Myo

Gorilla only

AML-1

Gorilla only

Human

GTGCCACCACGCCAGGCTAAT

Gorilla

GTGCCACCACACCAGGCTAGT

Human

CGCCAGGCTAATTTTTTTTT

S8, HFH-2

Gorilla

CACCAGGCTAGTTTTTTTT

SRY

Human

TTTTTTTTT__TTTGTATTTTT

Gorilla

TTTTTTTTGcgTGTGTATTTTT

Human

GTATTTTTAGTAGAGATGGGG

Gorilla

GTATTTTTAGCAGAGATGGGG

649

660, 669

660, 669
Gorilla only

No difference

678, 682
Gorilla only
692

No difference

Gorilla only

Gorilla only

Human

TTTCCTTCCAGATTTCAGTCCT

Gorilla

TTTCCTTCCAAATTTCAGTCCT

Lyf-1

953

Human

TTCAGTCCTATAACTTTGGAC

CdxA

Gorilla

TTCAGTCCTACAACTTTGGAC

966
all apes
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(Table 7: Continued)
Species

Sequence

Human

TTGGACTCCCAACAGATTAAG

Gorilla

TTGGACTCCCGACAGATTAAG

Human

AGATCCCTTTCCCAAGTGACA

Gorilla

AGATCCCTTTTCCAAGTGACA

Human

TTGCAGTGAGCTGAGATTGTGC

Gorilla

TTGCAGTGAGCCGAGATTGTGC

Human

TGTGCCACTGTGCTCCAGCCT

Gorilla

TGTGCCACTGCGCTCCAGCCT

Exclusive TFBS
Ik-2

cap, AP-4

1345
No difference
Skn-1
AP-1

Human

TGAAAACAAGGATAGAAATGT

Gorilla

TGAAAACAAGAATAGAAATGT

Human

AACTTTACTACTTATGAGTGT

Gorilla

AACTTTACTATTTATGAGTGT

1330
all apes

CCTGGATGACAGAGCAAGACTCTGTCTCA

AAAAAAAAAACAAAAAACAAA

1094
Gorilla only

CCTGGGTGACAGAGCGAGACTCCGTCTCA

AAAAAAAAAAAAAAAAACAAA

981

USF, Ik-2

Gorilla

Gorilla

Position

Gorilla only

Human

Human

Occurrence

all apes
1358, 1375
all apes

BR-C Z,

1394
all apes
1429

No difference

all apes
1595

BR-C Z

all apes

Table 7: The sequences of human and gorilla were aligned and variable nucleotides
between the species were noted. The variable nucleotide plus 10 nucleotides before and
after were put into the TFSEARCH transcription factor binding site prediction program.
The predicted transcription factors that are exclusive to one species are noted on the same
line as that species’ nucleotide sequence. The occurrence of that change in one or more
species is also noted. There were 31 nucleotide changes between human and gorilla, 17 of
these were specific to gorilla and resulted in a loss of 12 transcription factor binding sites
that were predicted to be in human.
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3.13 Transcription factor binding sites may cause differential expression
Predicted transcription factor binding site differences were compared to regions
that are highly conserved across mammals or have been previously identified as involved
in the regulation of ACPP. There are 4 nucleotide changes in bonobo that produced a gain
of 8 predicted transcription factor binding sites that occurred in regions responsible for
upregulation or downregulation of expression as identified by Zelivianski et al. (2002),
however no changes occurred in regions that are highly conserved. In gorilla, there were
a total of 9 nucleotide changes that produced 11 different predicted transcription factor
binding sites in regions of upregulation or downregulation. A single change occurred in a
peak of high conservation from position 133,518,721 to 133,518,804. This nucleotide
change resulted in a loss of the Ik-2 transcription factor binding site in gorilla (Figure 13).
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Figure 13: Location of changes in predicted transcription factor binding sites
between human-bonobo and human-gorilla. The location of the changes in predicted
transcription factor binding sites aligned with other elements in the ACPP promoter show
that only 1 change, found in gorilla, is located in a region of high conservation. This
change in transcription factor binding site Ik-2, is highlighted with an arrow. A number of
changes in both bonobo and gorilla occur in regions identified to be important in
upregulation or downregulation of transcription.
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Chapter 4
Discussion
4.1 Experimental Considerations
4.1.1 The human ACPP reporter construct drives expression higher than the
empty vector
It was determined that the human ACPP promoter construct is able to drive
transcription to significantly higher levels than the empty vector by comparing the
relative luminescence of each. The pGL4.10 [luc2] reporter vector contains no promoter
and one would expect to see increased expression after the correct ligation of the ACPP
upstream region of the luciferase reporter gene if it truly functions to promote
transcription. In initial transient transfection experiments, the expression of the human
ACPP construct was compared to the empty pGL4.10 [luc2] vector under no treatment
and with 10 nM R1881, a synthetic androgen. The human promoter did have higher
expression than the empty vector under both conditions. Others have previously
suggested that a very conservative criteria for defining promoter activity is a > 10-fold
increase in activity over the empty vector, and a more liberal definition of 2-fold or
greater (Hoogendoorn et al., 2003; Chabot et al., 2007). Since the 1.7 kb human ACPP
upstream region had previously been shown to effectively drive transcription (Shan et al.,
1997, 2003; Zelivianski et al., 2002) the requirement of a 10-fold increase is overly
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conservative. In all of our experiments the magnitude of increase ranged from 2 to 5.
Thus, we can conclude that our in vitro reporter system if functioning and that further
experiments including the expression levels between hominoid species would be a
reliable comparison.

4.1.2 Problems and Inconsistencies
The relative luminescence ratios for the expression by the human ACPP construct
varied from week-to-week (Figure 12). For the first transfection experiments, the mean
ratio of luminescence is 2 to 5 times greater than the mean from other weeks. These first
transfection experiments also had much higher standard errors (Figure 12). The data from
subsequent weeks were more consistent under all experimental conditions and had lower
standard errors. This could be caused by a few potential sources. First, the transfections
in which the ratios were abnormally high were the first transfections performed and
human error in properly performing the techniques may be a cause. Second, different
DNA preps may not be of the same purity and cells may not react similarly to each prep.
Third, cell culture conditions may also influence luminescence. Different culture
environments, including small changes in pH, CO2 levels, humidity, or batch of reagents
may influence the efficiency of the reaction. Because data from subsequent weeks have
very small standard errors, it is unlikely that machine or pippetting error is a major source
of variation. Other than the first transfections, all subsequent experiments have high
consistency between individual transfections within one week and are likely reliable data.
Some suggested solutions for the weekly variation include repeating the experiments
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under the same experimental conditions, including the same batch of medium and serum,
and re-purifying the human ACPP construct.
Chimpanzee was not included in the transient transfection experiments because of
difficulty cloning the promoter into the TOPO TA and pGL4.10 [luc2] vectors. A
restriction digest of this region in chimpanzee revealed an extra digestion site and
subsequent attempts to clone in the promoter of other individuals also failed in both the
TOPO TA and luciferase reporter vectors. This is not entirely problematic because of the
high similarity between chimpanzee and bonobo; however, future experiments include
creating the chimpanzee construct by making small procedural changes and repeating
transient transfection experiments.
The first attempts at cloning the ACPP promoter into a vector included inserting
the promoter directly into the pGL4.10 [luc2] vector. This had a low success rate and it
was determined that cloning first into a TOPO TA vector could improve results.
Subsequent cloning efforts were performed by TOPO TA cloning and purifying the insert
from this vector for ligation into the luciferase reporter vector. Even after this
modification, cloning efficiency was still lower than desired. PCR was used to screen all
colonies before purification of the plasmid.
At first, mini-prep plasmid purification of a 50 ml culture was performed to purify
the TOPO TA vector containing the ACPP promoter. A restriction digest of this product
produced the promoter fragment that was to be gel purified and ligated into the luciferase
reporter vector. Because a large amount of product was lost through gel purification,
larger digest reactions were performed and as a result, more purified plasmid was needed.
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The midi-prep method of a 50 ml culture became the preferred method of purification
after determining that the quantity of DNA produced by the midi-prep purification would
be more beneficial to subsequent experiments.

4.2 Levels of expression in bonobo and gorilla are consistent with mating
behaviors
Chimpanzees and bonobos have a multimale/multifemale mating system in which
the females mate with a large number of males per reproductive cycle (Goodall, 1986).
They experience high levels of sperm competition and are the only hominoids to produce
a copulatory plug (Dixson 1998 b). Many seminal proteins appear to have evolved under
positive selection in chimpanzee (Clark and Swanson, 2005; Carnahan and JensenSeaman, 2008). Gorillas are polygynous and likely experience little or no sperm
competition. Some seminal proteins in gorillas are nonfunctional and are likely
pseudogenes (Jensen-Seaman and Li, 2003; Carnahan and Jensen-Seaman, 2008).
Humans are intermediate in the amount of sperm competition expected by their mating
systems. In the transient transfection experiments of the pGL4.10 [luc2] constructs
containing the hominoid ACPP promoter, the levels of expression produced by the
constructs is proportional to the level of sperm competition in each species. The
expression by the bonobo promoter is higher than all other hominoid species, while the
gorilla expression is much lower than any other hominoid species. Human, orangutan,
and gibbon expression levels were intermediate of the high and low extremes of bonobo
and gorilla. While humans, gorillas, and gibbons are all expected to be experiencing no or
low levels of sperm competition, gorilla may have the least sperm competition because of
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the strong male-male physical competition that may prevent extra matings in gorilla
females, more so than in the other hominoid species.
ACPP has the ability to cleave the semenogelins and liquefy ejaculated semen
(Brillard-Bourdet et al., 2002). Increased expression of ACPP in bonobo may be
occurring for a number of reasons. One possibility includes quicker degradation of the
copulatory plug that was previously deposited by another male. Increased expression of
this protein would be a reproductive strategy for a male to liquefy the first plug and
deposit their own semen closer to the cervix of the female for an increased chance of
fertilizing the egg. Another possibility includes degradation of one’s own copulatory
plug. With sperm being trapped inside the thick coagulum, more rapid liquefaction of
one’s own copulatory plug would allow the sperm to more quickly regain their motility
and travel towards fertilization of the egg. Finally, increased expression of ACPP may be
the result of scaling with ejaculate volume. Chimpanzees and bonobos have increased
testes size (Harcourt et al., 1981) however data regarding volume of ejaculate is variable
and may reflect method of collection as well as environment (captive or free) of the
individual. Ejaculate volume estimates range from 1 ml (Martin and Gould, 1977) to 7 ml
(Dixson, 1998b), compared to the human average of 2.5 ml (Martin and Gould, 1977). It
would be interesting to determine if the increased expression of ACPP is consistent with
increased ejaculate size, or if the concentration is higher in a smaller volume of ejaculate.
Low expression levels in gorilla may also be explained similarly. A number of seminal
proteins are pseudogenes in gorilla, as evidenced by the presence of premature stop
codons; however, ACPP is not one of those genes (Clark and Swanson, 2005). While the
protein coding sequence remains functional, changes in the regulation of the gene may be
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responsible for the low levels of expression. Also, since gorilla has a smaller ejaculate
volume than any of the other hominoid species, 0.4 ml, (Martin and Gould, 1977) the
expression may be scaled to be proportional to concentrations in other volumes.
Macaque, which has a multimale/multifemale mating system similar to chimpanzee and
bonobo, also had significantly higher expression than many of the hominoids in the no
treatment experiment. This study did not include Cercopithecoid relatives of macaque,
however future experiments examining expression levels between Old World monkeys
with varying mating systems would be interesting.

4.3 Evolution at both levels
Changes that are responsible for phenotypic differences between species are likely
the result of differences in the regulatory regions as well as the protein coding regions of
genes (King and Wilson, 1975). The question that this study sought to answer was
whether there was evidence for evolution of ACPP in both levels in the hominoids. From
previous studies, the elevated Ka/Ks ratio in the chimpanzee lineage (1.16) is evidence
for positive selection in the protein coding region of ACPP (Clark and Swanson, 2005).
Increased expression levels seen in these luciferase assays also points to selection
occurring in regions responsible for regulating ACPP expression. While other genes may
be pseudogenes in gorilla, the coding region of ACPP appears to be functional (Clark and
Swanson, 2005). Given the extremely low expression levels in the luciferase assays, little
or no ACPP may be produced in gorilla, although of course in vitro results may not
necessarily be reflecting what is happening in vivo. Based on the differential expression

66

among hominoids in the transient transfection experiments as well as data from others on
the protein coding regions of ACPP, I conclude that ACPP is evolving at both the protein
and regulatory level in hominoids in response to sexual selection.

4.4 Using TFBS to predict potential causes of differential expression
Regions that are essential for the regulation of gene expression may be located in
areas that are highly conserved across mammals or vertebrates (Vavouri and Elfgar,
2005). Changes in these regions are likely to result in large expression differences.
Transcription factor binding site prediction programs were used to determine if speciesspecific nucleotide differences in the 1.7 kb region of the ACPP promoter contained in
the bonobo or gorilla reporter constructs resulted in a gain or loss of transcription factors
predicted in these highly conserved regions. Compared with predictions from the human
1.7 kb ACPP promoter sequence, gorilla lost one predicted factor, Ik-2, in a region that
was highly conserved. The Ikaros transcription factor family is restricted to lymophcyte
expression (Molnár and Georgopoulos, 1994) and therefore is does not likely explain the
dramatic decrease in expression by the gorilla ACPP construct. Bonobo had no predicted
changes in transcription factor binding sites in these regions compared to human. Other
lines of evidence suggest that smaller, species-specific changes in gene expression may
occur in regions that occur outside of highly conserved areas. Buckland et al. (2004)
determined that up to 35% of human polymorphisms in promoters cause functional
differences in expression and that the majority of these polymorphisms are not in
conserved regions, or in regions containing a predicted transcription factor binding site.
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Also, an estimated 32-40% of functional transcription factor binding sites in human are
not functional in rodents, indicating a high turnover of transcription factor binding sites
(Dermitzakis and Clark, 2002). The absence of many functional human transcription
factor binding sites in rodents is further evidence for searching for hominoid-specific
changes in regulation in areas outside of those conserved in mammals. When looking
outside the highly conserved regions, a number of predicted differences occur between
human and either bonobo or gorilla in the 1.7 kb region of ACPP from the reporter
construct. It is likely that these changes are in part responsible for the differential
expression of ACPP that is found among the hominoids. One way to determine which of
these changes by itself or in combination is responsible for changes in expression
includes site-directed mutagenesis to target individual nucleotide differences and measure
expression levels. This method has been successful for others (Chabot et al., 2007) and
would be an interesting future direction for this body of work.
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Appendix 1: Alignment of Hominoid ACPP Construct (-1593 to +117)
Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG
CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG
CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG
CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG
CACATTCCAGGGCAT-CCTATGATCACATAAGAACACAATCCTCCTGCCACAGGTAAGCG
CACGTTCCAGGGCATTCCTATGATCACATAAGAACACAATCCTCCTGCCACAGCTAAGTG
CACATTCCAGGGCAT-CCGATGATCACATAAGAACACACTCCTCCTGCCACAGGTAAGCG
*** *********** ** ******************* ************** **** *

59
59
59
59
59
60
59

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

CAATGTACCAGGAAACAGGTTGCGGGTAAACCATTGTTCTCCCTCTGCCATTATGATAGA
CAATGTACCAGGAAACAGGTTGCGGGTAAACCATTGTTCTCCCTCTGCCATTAGGATAGA
CAATGTACCAGGAAACAGGTTGCGGGTAAACCATTGTTCTCCCTCTGCCATTAGGATAGA
CAATGTACCATGAAACAGGTTGCGGGTAAACCATTTTTCTCCCTCTGCCATTAGGATAGA
CAATGTACCAGGAAACAGGTTGTGGGTAAACCATTGTTCTCTCTCTGCCATTAGGATAGA
CAATGTACCAGGAAACAGGTTGTGAGTAAACCATTGTTCTCCCTCTGCCATTAGGACAGA
CAATGTACCCGGAAATGGGTTGTGGGTAAACCGTTGTTCTCCCTCTGCCATTAGGATAGG
********* **** ***** * ******* ** ***** *********** ** **

119
119
119
119
119
120
119

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

AATATCATGACAGGCAGCTCTGCCCCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT
AATATCATGACAGGCAGCTCTGCCCCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT
AATATCATGACAGGCAGCTCTGCCCCCAAATCTTGCAAAATCWCAATGTGCACCTCAAGT
AATATCATGACAGGCAGCTCTGCCCCCACATCTTGCAAAATCTCAATGTGCACCTCAAGT
AATATCATGACAGGCAGCTCTGCCCCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT
AATATCATGACAGGCAGCTCTGCCTCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT
AATGTCATGACAGGTAGCTCTGCCCCCAAATCTTGCAAAATCTCAATGTGCACCTCAAGT
*** ********** ********* *** ************* *****************

179
179
179
179
179
180
179

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC
TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC
TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC
TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC
TTGTATTGTTTTAGCCTATGATGGAACTGACAGGTTGGGGAAAACGGAAAGCAAAGTTCC
TTGTATTGTTCTAGCCTACGATGGAACTGACGGGTTGGGGAAAATGGAAAGCAAATTTCC
TTGTATTGCTTTAGCCCATGATGGAACTGACAGGTTGGGGAAAATGGAAAGCAAAGTTCC
******** * ***** * ************ ************ ********** ****

239
239
239
239
239
240
239

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

ATCAGTCTGGATCGCCTTTTGTAGTGTCCCCAGTGAGATCATAGCTGGAGAGGCAAGGAT
ATCAGTCTGGATCGCCTTTTGTAGTGTCCCCAGTGAGATCATAGCTGGAGAGGCAAGGAT
ATCAATCTGGATCGCCTTTTGTAGTGTCCCCAGTGAGATCATAGCTGGAGAGGCAAGGAT
RTCAGTCTGGATCGCTTTTTGTAGTGTCCCCAATGAGATCATAGCTGGAGAGGCAAGGAT
ATCAGTCTGGATCGCCTTTTGTAGTGTCCCCAATAAGATCATAGCTGGAGAGGCAAGGAT
ATCAGTCTGGATTGTCTTTTGTAGTGTCCCCAATGAGATCATAGGTGGAGAGGCAAGGAT
ATCAGTCTGGATTGTATTTTGTAGTGTCACCAATGAGATCATAGCTGGAGAGGCAAGGGT
*** ******* * ************ *** * ********* ************* *

299
299
299
299
299
300
299

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGTTGATGACTAATAATATAGAATTGT
GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGTTGATGACTAATAATATAGAATTGT
GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGTTGATGACTAATAATATAGAATTGT
GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGTTGATGACTAATAATATAGAATTGT
GTAACTCACTCAAAATTTAAGGCTTATGGCCAAAGGTGATGACTAATAATATAGAATTGT
GTAACTCACTCAAAATGTAAGGCTTATGGCCAAAGTTGGTGACTAATAATATAGAATTGT
GTAACTCACTAAAAATGTAAGGCTTATGGCCAAAGTTGATGACTAATAATACAGAATTAT
********** ***** ****************** ** ************ ****** *

359
359
359
359
359
360
359

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

AGGTTTGGGCTTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC
AGGTTTGGGCTTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC
AGGTTTGGGCTTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC
AGGTTTGGGCTTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC
AGGTTTGGGATTTTTGCTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC
AGGTTTGGGCTTTTTGTTTTCTTAAAAAACTCTGTCAGATTTGGAAAGGGACCACCAATC
AGGTTTGGGCTTTTTGTTTTCTTAAAAAACTCTGTCAGGTTTGGAAAGGGACCTCCAATC
********* ****** ********************* ************** ******

419
419
419
419
419
420
419
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Appendix 1 (continued)
Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

T-AATTTTGAGATACCACAGGTAATGTCCAATT-GTCTTAAGGTGTGACTAAAATTTTTC
T-AATTTTGAGATACCACAGGTAATGTCCAATT-GTCTTAAGGTGTGACTAAAATTTTTC
T-AATTTTGAGATACCACAGGTAATGTCCAATT-GTCTTAAGGTGTGACTAAAATTTTTC
T-AATTTTGAGATACCACAGGTAATGTCCAGTT-GTCTTAAGGTGTGACTAAAATTTTTC
T-AATTTTGAGATACCACAGGTAATGTCCAATT-GTCTTAAGGTGTGACTAAAATTCTTC
CTAGTTTTGAGATACCACAGGTAATGTCTAATT-GTCTTAAGGTGTGACTAAAATTTTTC
CCAATTTTGAGATGCCACGGGTAATGTCCAATTTGTCTTAAGGTGTGACTAAAATTTTTC
* ********* **** ********* * ** ********************** ***

477
477
477
477
477
479
479

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

TTTTGTTT-GTTTTTTGTTGTTGTTTGTTTGTTT----TGCTGTGTTTTGAGATGGAGTC
TTTTGTTT-GTTTTTTGTTGTCGTTTGTTTGTTT----TGTTGTGTTTTGAGATGGAGTC
TTTTGTTT-GTTTTTTGTTGTCGTTTGTTTGTTTGTTTTGTTGTGTTTTGAGATGGAGTC
TTTTGTTT-GTTTTTTGTTGTTGTTTGTTTGTTTGTTTTGTTTTGTTTTGAGATGGAGTC
TTTTTTTTTGTTTGTTGTTGTTTTTTGTTTGTTT----TGTTTTGTTTTGAGATGGAGTC
TTTTGTTT-TTTGTTTGTTGTTGTTTATTTGTTTATTTTGTTTTGTTTTGAGATGGCATC
TTTGTTGT----TGTTGTTGTT-TTTGTTTGTTT-----GTTTCGTTTTGAGATGGAGTC
*** * *
******* *** *******
* * ************ **

532
532
536
536
533
538
529

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

TTGCTCTGTCACTCAGGCTGGAGTGCAGT-GGCACAATCTCGGCTCACTGCAACCTCCAC
TTGCTCTGTCACTCAGGCTGGAGTGCAGTTGGCACAATCTCGGCTCACTGCAACCTCCAC
TTGCTCTGTCACTCAGGCTGGAGTGCAGT-GGCACAATCTCGGCTCACTGCAACCTCCAC
TTGCTCTGTCACTCAGGCTGGAGTGCAGT-GGCACAGTCTCAGCTCACTGCAACCTCCAC
TTGCTCTGTCACTCAGGCTGGAGTGCAGT-GGCACAATCTCAGCTCASTGCAACCTCCAC
TTGCTCTGTCACCCAGGCTGGAGTGCAGT-GGCACAATCTCGGCTCACTGCAACCTCCAC
TTGCTCTGTAGCCCAGGCTGGAGTGCAGT-GGCACAATCTCGGCTTACTGCAACCTTCAC
********* * **************** ****** **** *** * ******** ***

591
592
595
595
592
597
588

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

CTCCTGGGTTCAAGTGACTCTCCTGCCTC-GCCTCCCAGGTAGCTGGGACTATAGGCATG
CTCCTGGGTTCAAGTGACTCTCCTGCCTC-GCCTCCCAGGTAGCTGGGACTATAGGCATG
CTCCTGGGTTCAAGTGACTCTCCTGCCTC-GCCTCCCAGGTAGCTGGGACTATAGGCATG
CTCCTGGGTTYAAGTKACTCTCCTGCCTC-GCCTCCCAGGTAGCTGGGACTATAGGCAGG
CTCCTGGGTTCAAGTGACTCTCCTGCCTC-ACTTCCCAGGTAGCTGGGACTACAGGCATG
CTCCTGGGTTCAAGTGACTCTCCTGCCTCAGCCTCCCAGGTAGCTGGGACTACAGGCATG
CTTCTGGGTTCAAGTGATTCTCCTGCCTCAGTCTCCCAGGTAGCTGGGACTACAGGCATG
** ******* **** * ***********
******************* ***** *

650
651
654
654
651
657
648

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

TGCCACCACGCCAGGCTAATTTTTTTTT--TTTGTATTTTTAGTAGAGATGGGG-TTTCA
TGCCACCACGCCAGGCTAATTTTTTTTT--TTTGTATTTTTATTAGAGATGGGG-TTTCA
TGCCCCCACGCCAGGCTAATTTTTTTTT--TT-GTATTTTTATTAGAGATGGGG-TTTCA
TGCCACCACACCAGGCTAGTTTTTTTTGCGTGTGTATTTTTAGCAGAGATGGGG-TTTCA
TGCCACCATGCCCAGCTAAAATTTTTYT----TGTATGTTTAGTAGAGATGGGG-TTTCA
TGC-ACCATGCCCAGCTAATTTTTTTGT--TGTATATTTTTAGTAGAGATGGGGGTTTCA
TGCCACCACGCCCAGCTAATTTTTTTTT-----GTATTTTTAGTAGAGATGGGG-TTTCA
*** *** ** ****
*****
*** **** ********** *****

707
708
710
713
706
714
702

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

CCATGCTGGCCAGGCTGGTCTT-AACTCCTGACCTCAAGTGATCTGCCCACCTCGGCCTC
CCATGCTGGCCAGGCTGGTCTT-AACTCCTGACCTCAAGTGATCTGCCCACCTCAGCCTC
CCATGCTGGCCAGGCTGGTCTT-AACTCCTGACCTCAAGTGATCTGCCCATCTCAGCCTC
CCATGCTGGCCAGGCTGGTCTT-AACTCCTGACCTCAAGTGATCTGCCCACCTCGGCCTC
CCATGCTGGCCAGGCTGGTCTTGAACTCCTGACC-CAAGTGATCTGCCCACCTCGGCCTY
CCATGCTGGCCAGGCTGGTCTCGAACTCCTGACCTCAAGTGATCTGCCCGCCTCGGCCTC
CCATGCTGGCCAGGCTGGTCTTGAACTCCTGACCTCAAGTGATCTGCCCACCTCGGCCTC
********************* *********** ************** *** ****

766
767
769
772
765
774
762

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

CCAAAGTGCTGGGATTACAGACATGAGCCACCACGCCCAGCCTAAAATTTTTCAAAATAA
CCAAAGTGCTGGGATTACAGACATGAGCCACCACGCCCAGCCTAAAATTTTTCAAAATAA
CCAAAGTGCTGGGATTATAGACATGAGCCACCACGCCCAGCCTAAAATTTTTCAAAATAA
CCAAAGTGCTGGGATTACAGACATGAGCCACCACGCCCAGCCTAAAATTTTTCAAAATAA
CCAAARTGMWGGGATTACAGACCTGAGCCACCAGGCCCAGCCTAAAATTTTTCAAAATAA
CCAAAGTGCTGGGATTACAGACGTAAGCCACCACACCCAGCCTAAAATTTTTCAAAATAA
CCAAAGTGCTGGGATTACAGACGTAAGTCACCATGCCCAGCCTAAAATTTTTCAAAATAA
***** ** ******* **** * ** ***** *************************

826
827
829
832
825
834
822
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Appendix 1 (continued)
Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

Conserved Region 3
ACTTGCTGTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT
ACTTGCTGTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT
ACTTGCTGTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT
ACTTGCTGTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT
ACTTGCTCTTACTTCTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT
ACTTGCTCTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT
ACTTGCTCTTACTTTTCTTCTTTAATTTAAAAATACCTCTATAGGCTACATGAGAGTTTT
******* ****** *********************************************
TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC
TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC
TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC
TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC
TGAAAAAGTAGCCATGTTTGGCATGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC
TGAAAAAGTATCCATGTTTGGATTGGAAATAGGCCCCAAATATGTCAACACCTGTATTTC
TGAAAAAGTAGCCATATTTGGCATGGAAATAGGCCTTAAATATGTCAATACTTGTATTTC
********** **** ***** ************ *********** ** ********
Conserved Region 2
CTTCCAGATTTCAGTCCTATAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG
CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG
CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG
CTTCCAAATTTCAGTCCTACAACTTTGGACTCCCGACAGATTAAGAATCACTGGTCTAAG
CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG
CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG
CTTCCAGATTTCAGTCCTACAACTTTGGACTCCCAACAGATTAAGAATCACTGGTCTAAG
****** ************ ************** *************************

886
887
889
892
885
894
882

946
947
949
952
945
954
942

1006
1007
1009
1012
1005
1014
1002

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAAGTGACAGCCACAAATCCAACGCTGTATC
GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAAGTGACAGCCACAAATCCAACGCTGTATC
GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAAGTGACAGCCACAAATCCAACGCTGTATC
GTTTCTAAAGTCAGGGTAGATCCCTTTTCCAAGTGACAGCCACAAATCCAACGCTGTATC
GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAAGTGACAGCCACAAATCCAACACTGTATC
GTTTCTAAAGTCAGGGTAGATTCCTTTCCCAAGTGACAGCCACAAAGCCAATGCTGTATC
GTTTCTAAAGTCAGGGTAGATCCCTTTCCCAA-TGACAGCCACAAAGCCA-CGCTGTATC
********************* ***** **** ************* ***
*******

1066
1067
1069
1072
1065
1074
1060

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

ATACCCTATCTAAAGAAAAGATAAAAGTAAACTGGCTTGGCACAGTGGCTCATGCCTGTA
ATACCCTATCTAAAGAAAAGCTAAAAGTAAACTGGCTTGGCACAGTGGCTCATGCCTGTA
ATACCCTATCTAAAGAAAAGCTAAAAGTAAACTGGCTTGGCACAGTGGCTCATGCCTGTA
ATACCCTATCTAAAGAAAAGATAAAAGTAAACTGGCTTGGCACAGTGGCTCATGCCTGTA
ATACC-TACCTAAAAAAAAGATAAAAGTAAACTGGCAGGGCACGGTGGCTCATGCCTGTA
ATACCCTATCTAAAGAAAAGATAAAAGTAAACTGGCAGGGCACGGTGGCTCATGCCTGTA
ATACCCTATCTAAAGAAAAGATAAAAGTAAACTGGCAGGGCACAGTGGCTCACGCCTGTA
***** ** ***** ***** *************** ***** ******** *******

1126
1127
1129
1132
1124
1134
1120

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

ATCTCAGCACTTTGGGAGGCCAAGGCAGGCGGATCATGCGGTTAGGAGTTGGAGACCAGC
ATCTCAGCACTTTGGGAGGCCAAGGCAGGCAGATCATGCGGTTAGGAGTTGGAGACCAGC
ATCTCAGCACTTTGGGAGGCCAAGGCAGGCAGATCATGCGGTTAGGAGTTGGAGACCAGC
ATCTCAGCACTTTGGGAGGCCAAGGCAGGCGGATCATGYGGTTAGGAGTTGGAGACCAGC
ATCTCAGCACTTTGGGAGGCCGAGGCAGGCAGATCGTGTGGTTAGGAGTTGGAGACTAGC
ATCTCAGCACTTTGGGAGGCCGAGGCAGGTGTATCATGTGGTTAGGAGTTGGAGACCAGC
ATCTCAGCACTTTGGGAGGCTGAGGCAGGTGGATTACGAGGTCAGGAGTTCGAGACCAGC
******************** *******
**
* *** ******* ***** ***

1186
1187
1189
1192
1184
1194
1180

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

CTAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTCGCCGGGTGTGGTG
CTAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTCGCCGGGTGTGGTG
CTAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTCGCCGGGTGTGGTG
CTAACCAACATGGTGAAACCCCRTCTCTACTAAAAATACAAAAATTCGCCGGGTGTGGTG
CTAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCGGGTGTGGTG
ATAACCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCCGAGTGTGGTG
CTAACCAACATGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGCCAGGTGTGGTG
******************** *********************** *** ********

1246
1247
1249
1252
1244
1254
1240
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Appendix 1 (continued)
Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

GTGCACGCCTGTAATCCCAGCTACTCAGGAAGACTGAAGCAGGAGAATTGCTTGAACCTG
GTGCACGCCTGTAATCCCAGCTACTCAGGA-GACTGAAGCAGGAGAATTGCTTGAACCTG
GTGCACGCCTGTAATCCCAGCTACTCAGGA-GACTGAAGCAGGAGAATTGCTTGAACCTG
GTGCACGCCTGTAATCCCAGCTACTCAGGA-GACTGAAGCA---GAATTGCTTGAACCTG
GCGCCCGCCTGTAATCCCAGCTACTCAGGA-GGCTGAAGCAGGAGAATTGCTTGAACCTG
GCGCGCGCCTATAATCCCAGCTACTCAGGA-GGCTGAAGCAGGAGAATTGCTTGAACCTG
GCGCATGCCTGTAATCCCAGCTACTCAGGA-GGCTGAGGCAGGAGAATTGCTTGAACTCA
* ** **** ******************* * **** ***
*************

1306
1306
1308
1308
1303
1313
1299

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

GGAGGCGGAGTTTGCAGTGAGCTGAGATTGTGCCACTGTGCTCCAGCCTGGATGACAGAG
GGAGGCGGAGTTTGCAGTGAGCCGAGATTGTGCCACTGCGCTCCAGCCTGGGTGACAGAG
GGAGGCGGAGTTTGCAGTGAGCCGAGATTGTGCCACTGCGCTCCAGCCTGGGTGACAGAG
GGAGGCGGAGTTTGCAGTGAGCCGAGATTGTGCCACTGCGCTCCAGCCTGGGTGACAGAG
GGAGACGGAGTTTGYAGTGAGCCCAGATTGTGCCACTGCGCTCCAGCCTGGGTGACAGAG
GGAGGCGGAGTTTGCAGTGAGCCGAGATAGCGCCACTGCGCTCCAGCCTGGGTGACAGAG
GGAGGCGGGCTTTGCAGTGAGCCAAGATCGTGCCACTGCACTCCAGCCTGGGTGACAGAG
**** *** **** ******* **** * ******* *********** ********

1366
1366
1368
1368
1363
1373
1359

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

1418
1426
1427
1427
1411
1433
1406

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

CAAGACTCTGTCTCAAAAAAA--------AAAAAACAAAAAACAAAGATAAAAGTAAACT
CGAGACTCCGTCTCAAAAAAACAAAAAACCAAAAAAAAAAAACAAAGATAAAAGTAAACT
AGAGACTCCATCTCAAAAAAA-AAAAAAAAAAAAAAAAAAAACAAAGATAAAAGTAAACT
CGAGACTCCGTCTCAAAAAAA-AAAAAAAAAAAAAAAAAAAACAAAGATAAAAGTAAACT
CGAGACTCKGTCTCAAAAAAA------------AAAAAAAAAAAAAGATAAAAGTAAACT
CGAGACTCCGTCTCAAAAAAAAAAAAAAXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
CAAAACTCCGTCCAAAAAAAA-------------AATAATAATAATGATAAAAGTAAACT
* **** ** *******
Conserved Region 1
GAAAACAAGGATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCC
GAAAACAAGAATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCT
GAAAACAAGAATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCT
GAAAACAAGAATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCC
GAAAACAAGAATAGAAATGTCTGCTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCC
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
GAAAACAAGAATAGAAATGTGTACTAACATGCTCTGTGACCTTGATCAACAGCTTTCCCC

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT
GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT
GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT
GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT
GCTCTTGGCCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAT
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
ACTCTTGACCTTGGTGTCCTAACTTAAATGGGGAAACTGTGATCTCTCTCAGCTCAAAAA

1538
1546
1547
1547
1531
1553
1526

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

TTACATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTACT 1596
TTACATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1604
TTACATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1605
TTACATGACAT-ATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1604
TTACATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1589
XXXXXXXXXXXXXXXXXXXXATTCCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1613
TTATATGACATTATTTACATA--CCAAACCTGCCCTACGCTTCCTGGAAACTTTACTATT 1584
•
*********************************** *
•
Conserved Region 4
TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1656
TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1664
TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1665
TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1664
TATGAGTGTGGCTCCTCCTTCCCTTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1649
TATGAGTGTGACTCCTCCTTCCCTTTCAATCCCTTAATTAAAAAGCTTCCCCTCTACAGG 1673
TATGAGTGTGGCTCCTCCTTCC-TTTCAATCCCTTAATTAAATAGCTTCCCCTCTACAGG 1643
********** *********** ******************* ****************

Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque
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1478
1486
1487
1487
1471
1493
1466

Appendix 1 (continued)
Human
Chimp
Bonobo
Gorilla
Orangutan
Gibbon
Macaque

CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATG
CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATG
CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATG
YTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCCTCAACATG
CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCTTCAGCATG
CTTTTGAAGTGATAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTCTCTTCAACATG
CTTTTGAAGTGGTAGCAGTTCCTCCTAACTCCTGCCAGAAACAGCTGTCCTCAACATG
********** ********************************** ** *** ****
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1714
1722
1723
1722
1707
1731
1701

